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ABSTRACT 
 
Snama is the Drosophila melanogaster homologue of the human Retinoblastoma 
Binding Protein 6 (RBBP6) gene. While mammalian RBBP6 proteins have been 
shown to interact with tumour suppressor proteins such as RETINOBLASTOMA 
(Rb) and p53, this has not been determined in Drosophila melanogaster. 
Moreover, SNAMA proteins have yet to be experimentally verified. To date, 
studies have shown Snama to be involved in cellular proliferation, DNA 
metabolism and cell cycle control. In this study, we sought to identify and 
characterize SNAMA proteins through immunological and biochemical 
approaches. Poly-clonal chicken antibodies were raised against an amino-terminal 
fragment common to both putative SNAMA proteins and purified via pre-
adsorption. The antibodies were utilized in immunoblots – to investigate the 
spatio-temporal regulation, as well as in co-immunoprecipitation assays – to 
discover potential interaction partners of SNAMA proteins. Putative SNAMA-PA 
was not detected in this study. Acetylation of protein extracts, which has been 
shown to overcome the inability to visualize RBBP6 homologues, did not result in 
the detection of SNAMA-PA. Up-regulation of Snama-RA through camptothecin-
treatment also did not result in the detection of SNAMA-PA; neither did a 
selective precipitation procedure aimed at enriching extracts for RS-domain-
containing proteins, such as SNAMA-PA. As putative SNAMA-PB lacks the C-
terminal extension of putative SNAMA-PA, it could not be manipulated via these 
biochemical procedures. Regardless, a protein of 55 kDa – which is the expected 
mass of SNAMA-PB – was detected. Furthermore, the spatio-temporal regulation 
of this 55 kDa protein was consistent with that expected of putative SNAMA-PB; 
thus, this study has possibly verified the existence of SNAMA-PB. Furthermore, 
we have identified potential interaction partners – most significantly DREF – 
which is known to function in a similar capacity to the expected roles of SNAMA 
proteins, namely: cell cycle control and cellular proliferation.  
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    CHAPTER ONE 
  
1. INTRODUCTION 
 
A RING domain, found in the RETINOBLASTOMA BINDING PROTEIN 6 
(RBBP6) family, has been shown to impart these proteins with ubiquitin ligase 
activity (Antunes, 2008; Chibi et al., 2008). RBBP6 proteins also contain an 
amino-terminal domain called Domain-With-No-Name (DWNN), which is found 
exclusively in RBBP6 proteins and is highly similar to ubiquitin in terms of its 
tertiary structure (Mather, 2005; Mather et al., 2005; Pugh et al., 2006). 
Furthermore, the DWNN domain is also expressed as a stand-alone domain-
protein in mammals and may be representative of a putative form of ubiquitin-like 
modification (Pugh et al., 2006). These facts, taken together, suggest that the 
RBBP6 family of proteins are involved in protein modification by ubiquitination 
or ubiquitin-like mechanisms.  
 
RBBP6 proteins have also been implicated in other cellular functions, such as 
mRNA processing (Vo et al., 2001) and cell cycle control (Mather, 2005; Mather 
et al., 2005; Jones et al., 2006). Furthermore, Mus musculus RBBP6 has been 
demonstrated to facilitate MDM2-mediated ubiquitination of p53 (Li et al., 2007), 
thus implicating RBBP6 with cell cycle control and apoptosis. Despite 
involvement in all these diverse, yet crucial, cellular processes, little research has 
been carried out on this important family of proteins. For instance, only two 
crystal structures pertaining to the RBBP6 family of proteins exist: those of the 
DWNN domain (Pugh et al., 2006) and RING domain (Kappo et al., 2012) of 
Homo sapiens RBBP6. Furthermore, while two Drosophila melanogaster RBBP6 
transcripts are known to exist (Mather, 2005; Mather et al., 2005; Jones et al., 
2006; Daines et al., 2011), the resultant proteins have not been experimentally 
verified.   
 
This chapter begins by providing a very brief overview of the ubiquitin system. 
Thereafter, RBBP6 proteins in human and prominent model organisms, as well as 
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structural features of these proteins, are discussed. Particular emphasis is given to 
D. melanogaster, which forms the basis of this study. Lastly, this dissertation 
presents a contemporary account of known binding partners of RBBP6 proteins, 
as well as their characterized roles in these interactions. 
 
1.1 THE UBIQUITIN SYSTEM 
 
Ubiquitin is a highly evolutionarily conserved, 76 amino-acid (a.a.) protein, which 
is covalently attached onto substrates as a form of post-translational modification. 
The process of ubiquitin conjugation is well characterized and has been 
extensively reviewed by Hershko & Ciechanover (1998) – two of three joint-
winners of the 2004 Nobel Prize in Chemistry, for their work on ubiquitin. 
Briefly, the attachment of ubiquitin to a substrate (Figure 1.1) involves three key 
enzymes and is initiated by the conjugation of an ubiquitin molecule, at its Gly-76 
residue, to a Cys residue on an E1 ubiquitin-activating enzyme, with the input of 
ATP. This results in the formation of an activated ubiquitin-E1 complex. The 
activated ubiquitin is then transferred to an E2 ubiquitin-conjugating enzyme, also 
through thioester bond formation between a Cys on the E2 enzyme and Gly-76 of 
ubiquitin. Lastly, an E3 ubiquitin protein ligase – having bound to the substrate – 
then interacts with the E2-ubiquitin complex and catalyzes an amide bond 
between Gly-76 of ubiquitin and an ε-amino group of a specified Lys residue on 
the substrate. As the E3 ubiquitin ligase binds to the target of interest, it confers 
the greatest level of specificity of the reaction (Passmore & Barford, 2004). 
Indeed, this also manifests in the number of known E1, E2 and E3 enzymes: E1s 
are the least numerous, while E3s are the most abundant as well as substrate-
specific enzymes involved in ubiquitin conjugation.  
 
A substrate may be modified with a single ubiquitin protein or even a chain of 
multiple, linked ubiquitin molecules. In the case of the latter, a fourth enzyme – 
the E4 ubiquitin-chain elongation factor – is required for poly-ubiquitin chain 
formation (Koegl et al., 1999; Kuhlbrodt et al., 2005). It is still unknown whether 
E4s are absolutely essential or whether substrates can also be poly-ubiquitinated 
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through multiple rounds of the E1-E2-E3 cascade (Jung et al., 2009). The number 
of ubiquitin molecules attached, as well as the lysine residue of ubiquitin proteins 
involved in a poly-ubiquitin chain, determines the substrate’s fate. Mono-
ubiquitination of a substrate can impart a wide range of effects, such as altering 
the protein’s cellular localization, or affecting processes such as transcription and 
signal transduction (Hochstrasser, 2009). Poly-ubiquitination of a substrate 
involving Lys-76 to Lys-63 linked ubiquitin molecules has also been shown to 
impart a wide range of effects. However, the majority of poly-ubiquitin chains are 
formed between an ubiquitin protein conjugated via its Lys-76 onto Lys-48 of the 
previous ubiquitin molecule (Hershko & Ciechanover, 1998).  A chain of four 
such linked ubiquitin molecules is known to direct a substrate to the 26S 
proteasome, for destruction.  
 
The 26S proteasome consists of a 20S inner “core” and two outer 19S “caps”. The 
20S core is made up of four rings, each in turn made up of seven different 
subunits. The two inner rings, known as the beta rings, are responsible for 
degradation of a substrate. The two outer rings, known as the alpha rings, bind the 
two 19S caps. A variety of caps exist (reviewed in Jung et al., 2009), which can 
impart different functionalities for the proteasome. In the canonical 26S 
proteasome, the two 19S caps are responsible for regulating entry into the core, 
after first removing the poly-ubiquitin chain from a substrate and recycling the 
chain to monomers, for re-use. The caps are, therefore, also responsible for 
binding the poly-ubiquitin chain, consisting of four Lys-76 to Lys-48 linkages, 
attached to the substrate. Specificity of binding occurs in the form of ubiquitin-
binding domains (UBDs), which are present not only on the 19S caps but on all 
ubiquitin receptors. The UBDs are specific for a particular linkage involved in a 
poly-ubiquitin chain, as well as the length of the chain. This specificity occurs, in 
part, due to the different linkages having different spatial orientations (see Figure 
1.1); for e.g. Lys-76 to Lys-63 linkages form linear chains, whereas Lys-76 to 
Lys-48 linkages form kinked chains (Broemer & Meier, 2009).  
 
 
4 
 
 
 
Figure 1.1: The ubiquitin conjugation pathway and fate of ubiquitinated proteins. Ubiquitin is 
conjugated onto a substrate via a cascade involving three enzymes: E1, E2 and E3, with a fourth 
enzyme, E4, necessary for poly-ubiquitin chain formation. Ubiquitination of a substrate can have a 
wide range of effects. In the case of poly-ubiquitin chains, the linkages connecting successive 
ubiquitin molecules together affect the chains topology, which enables selectivity on ubiquitin 
binding domains.  
 
A form of post-translational modification closely-related to ubiquitination exists, 
which has been called ubiquitin-like modification (ULM). As with ubiquitin, 
ubiquitin-like proteins contain the same, conserved ubiquitin superfold 
(Welchman et al., 2005). Ubiquitin-like proteins are also conjugated onto lysine 
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residues of a substrate – often in competition with ubiquitin and each other 
(Bossis & Melchior, 2006). Presently, ubiquitin-like modifications are assigned to 
9 major classes (reviewed in Cajee et al., 2012). ULM also occurs in the same 
sequential manner of an E1-E2-E3 cascade, although ubiquitin-like modifiers 
have their own specific E1, E2 and E3 enzymes. Interestingly some variations 
exist – for e.g. SUMOylation (small ubiquitin-related modifier) has been shown to 
occur either with or without an E3 enzyme. In vitro, in the absence of an E3 
ligase, both conjugation and ligation of SUMO can be performed by the E2 
conjugating enzyme Ubc9 (Desterro et al., 1999; Okuma et al., 1999), with E3 
enzymes often enhancing the reaction. Like ubiquitination, ULM is also involved 
in diverse cellular processes. Furthermore, modification of a substrate with an 
ubiquitin-like protein can alter various characteristics of the substrate, such as its 
functionality and localization. The study of ULM is still relatively new compared 
to ubiquitination. As such, not only is our current knowledge of known 
components of ULM expected to expand, but also, new forms of ULM are likely 
to be discovered. One such putative form of ULM, DWNNylation, is discussed in 
Section 1.2.  
 
1.2 RBBP6 HOMOLOGUES AND PROTEIN PRODUCTS 
 
In a study aimed at discovering novel binding partners of the Homo sapiens 
RETINOBLASTOMA (RB) tumour suppressor protein, one of the isolated 
proteins was named RETINOBLASTOMA-BINDING Q-PROTEIN 1 (RBQ-1) 
(Saijo et al., 1995). This partial protein was the first recorded product produced 
from what would become known as the retinoblastoma binding protein 6 
(RBBP6) gene (Sakai et al., 1995).   
 
RBBP6 is a single-copy gene purportedly present in all eukaryotes, although it has 
not been found in prokaryotes (Pugh et al., 2006). Homologues of RBBP6 have 
been described in various model organisms. In Mus musculus, the gene was 
discovered independently by two research groups and named p53 associated                                                                                                                                                                                                                              
cellular protein-testes derived (PACT) (Simons et al., 1997) and proliferation 
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potential protein-related (P2P-R) (Witte & Scott, 1997). The Drosophila 
melanogaster RBBP6 homologue was characterized by our group, followed 
shortly afterwards by an unrelated research group. As a result, it too was given 
two different names: Snama (Mather, 2005; Mather et al., 2005) and mini-me 
(Jones et al., 2006). The Saccharomyces cerevisiae homologue was named mutant 
pcf11 extragenic suppressor 1 (MPE1) (Vo et al., 2001), whereas, more recently, 
the Caenorhabditis elegans homologue retinoblastoma-binding-protein-like-1 
(RBPL-1) has been described (Huang et al., 2013). Given the various names 
accorded in these model organisms, the HGNC-approved (Seal et al., 2011) name 
of RBBP6 will be used generically for all homologues of this gene and resultant 
protein products. 
 
With the exception of S. cerevisiae, all of the afore-mentioned species produce 
multiple RBBP6 proteins through alternative splicing. For example, in H. sapiens, 
three RefSeq (Priutt et al., 2005) RBBP6 transcripts exist: RBBP6-1 
(NM_006910.4) consists of all 18 exons, RBBP6-2 (NM_018703.3) lacks exon 
16, whereas RBBP6-3 (NM_032626.5) contains the first three exons only (Figure 
1.2). These three transcripts encode proteins of 1792 amino acids (a.a.) 
(NP_008841.2), 1758 a.a. (NP_061173.1) and 118 a.a. (NP_116015.2), 
respectively. 
 
 
Figure 1.2: Exons constituting H. sapiens RBBP6 transcripts. Exons 1-3 are common to all three 
RBBP6 isoforms.  
 
In M. musculus, only two RefSeq (Priutt et al., 2005) transcripts exist. 
NM_011247.2 is comprised of all 18 exons and is the equivalent of H. sapiens 
RBBP6-1. The second M. musculus RBBP6 transcript, NM_175023.3, is 
comprised of the first 3 exons only, thus it is equivalent to H. sapiens RBBP6-3. 
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Due to incomplete RefSeq (Priutt et al., 2005) records, a third M. musculus 
RBBP6 transcript (XM_006507470.1) is still officially predicted, even though 
Scott et al. (2005) demonstrated it to be the predominant splice version between 
NM_011247.2 and XM_006507470.1. Unsurprisingly, this predicted transcript is 
the equivalent of H. sapiens RBBP6-2, as it only lacks exon 16. Thus the first 
three exons are common to all RBBP6 transcripts in both H. sapiens and M. 
musculus. In fact, these first three exons encode a domain which is found at the 
amino-terminus of all species’ RBBP6 proteins. Moreover, this domain – called 
“Domain-With-No-Name” (DWNN) (Mather, 2005; Mather et al., 2005; Pugh et 
al., 2006) is found exclusively in RBBP6 proteins. 
 
Analysis of RefSeq (Priutt et al., 2005) RBBP6 proteins of the afore-mentioned 
species in ScanProsite (prosite.expasy.org/scanprosite/), reveals three highly 
conserved, structured domains present in most RBBP6 proteins (Table 1.1), which 
are described below. 
 
(i) DWNN DOMAIN 
As mentioned previously, the DWNN domain is the identifying feature of RBBP6 
proteins. While the DWNN domain has little sequence similarity to ubiquitin – for 
example, H. sapiens DWNN and ubiquitin share only 18 % sequence homology 
(Mather, 2005; Mather et al., 2005; Pugh et al., 2006) – the tertiary structure of 
the DWNN domain is highly similar to that of ubiquitin (Figure 1.3).  
 
A di-glycine motif, found at residues 75 and 76 in ubiquitin, serves in the covalent 
attachment of ubiquitin onto substrates. Interestingly, this di-glycine motif is also 
present in H. sapiens and M. musculus RBBP6 proteins, at residues 78 and 79, but 
is absent in RBBP6 orthologues. This has led to speculation that the DWNN 
domain may also be conjugated onto substrates in vertebrate species (Mather, 
2005; Mather et al., 2005; Pugh et al., 2006). This possible form of post-
translational modification has been termed DWNNylation (Pugh et al., 2006) 
although it remains, as yet, unproven.  
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Figure 1.3: Super-imposed 3-D structures of H. sapiens DWNN domain and ubiquitin. In both 
polypeptides, beginning at the amino-terminus, the secondary structural arrangement occurs as 
ββαβ. While ubiquitin contains a final, fourth beta-sheet, in DWNN it is split into two shorter beta-
sheets. Overall, these two polypeptides possess highly similar secondary and tertiary structures. 
DWNN domain (PDB: 2C7H) in blue and ubiquitin (PDB: 1UBQ) in red. Image generated using 
SPDBV version 3.7 with secondary structure analysis performed using PsiPred version 3.3 
(bioinf.cs.ucl.ac.uk/psipred/). 
 
(ii) ZINC FINGER DOMAIN 
The second structured domain, common to all RBBP6 proteins except for the two 
DWNN domain proteins (H. sapiens RBBP6-3 and M. musculus RBBP6-2), is a 
CCHC-type zinc finger. Zinc fingers are typically involved in nucleic acid 
binding; interaction partners and functions of RBBP6 proteins will be discussed in 
Section 1.4.  
 
(iii) ZINC FINGER-LIKE DOMAIN 
The last, structured domain common to most RBBP6 proteins is a cysteine-rich, 
zinc finger-like domain. ScanProsite analysis identifies this domain as a RING 
domain in all RBBP6 proteins listed in Table 1.1 which contain this third domain, 
except for NP_001032975.1 in which it is classified as a U-box. RING domains 
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were originally characterized by a sequence of eight conserved cysteine and 
histidine residues, which adopt a cross-brace arrangement and bind two zinc-ions 
(Borden, 2000; Freemont, 2000). The sequence of conserved residues in the 
canonical RING domain, which are responsible for binding zinc, occurs in the 
order C3HC4 (Lovering et al., 1993), in which the first zinc binding site is formed 
between C1,C2, C5 & C6, with C3, H4, C7 and C8 forming the second zinc binding 
site (Borden, 2000). Despite also adopting a cross-brace fold, the U-box domain 
does not contain these conserved cysteine and histidine residues and does not bind 
zinc-ions; instead, the U-box is stabilized by hydrogen bonds and salt bridges 
(Aravind & Koonin, 2000; Ohi et al., 2003). While both the RING domain and U-
box domains were found to be involved in the ubiquitin proteasome pathway, 
originally it was thought that only RING-containing proteins could perform E3 
ubiquitin ligase activity; U-boxes were considered E4s, or accessory proteins to 
E3s which are involved in poly-ubiquitin chain formation (Koegl et al., 1999). 
This view was later changed when it was demonstrated by Hatakeyama et al. 
(2001) that some U-boxes were also able to mediate E3 ubiquitin ligase activity. 
Furthermore, RINGs have been shown to reversibly bind divalent metal-ions other 
than Zn
2+
, such as Cu
2+
 (Lovering et al., 1993), Co
2+
 (Roehm & Berg, 1997) and 
Cd
2+
 (Lovering et al., 1993; Kappo et al., 2012). Moreover, RINGs were 
discovered in which a single, divalent metal-ion – chelating cysteine or histidine 
residue was replaced with a lesser-conserved residue, such as glycine or aspartate, 
often with the effect that only one metal-ion co-ordinating site would form. Taken 
together, the ability to bind different divalent metal-ions, as well as the occurrence 
of RING domains with backbone residues other than cysteine or histidine, is 
thought to impart binding and functional specificity for RING-containing proteins 
(Roehm & Berg, 1997; Borden, 2000).  
 
The three, structured domains, described above, have collectively been named the 
DWNN Catalytic Module (DCM) (Antunes, 2008). As the DCM has been shown 
to mediate ubiquitin ligase activity (Antunes, 2008; Chibi et al., 2008), it is 
thought that the DCM implicates RBBP6 proteins in protein turnover (Kappo et 
al., 2012). Most RBBP6 proteins also contain multiple, unstructured domains – 
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typically tracts enriched in particular amino acids, which are present after the 
DCM. Of particular importance in RBBP6 proteins are serine and arginine tracts – 
the regions of which overlap (Table 1.1). These two amino acids are mostly 
present as SR and RS dipeptides and form a domain called the RS-domain.  
 
The RS-domain is a common feature of both SR proteins, and SR-like proteins. 
Initially, SR proteins were discovered as a group of proteins with a shared 
phosphoepitope, as detected by a monoclonal antibody: mAb 104 (Roth et al., 
1990). Follow-up studies utilizing this same antibody (Roth et al., 1991; Zahler et 
al., 1992) revealed an identical banding pattern (proteins with conserved sizes of 
20, 30, 40, 55 and 75 kDa), in immunoblots prepared from numerous species, 
including D. melanogaster and H. sapiens. Furthermore, these six proteins (two 
proteins of 30 kDa were discovered) were all shown to be involved in splicing 
activities, and contain an amino-terminal RNA recognition motif (RRM) and a 
carboxyl-terminal RS-domain (Zahler et al., 1992). Moreover, these proteins 
could be purified to homogeneity through a biochemical approach which involved 
two precipitation steps, employing ammonium sulphate and magnesium chloride 
(Roth et al., 1991; Zahler et al., 1992). Thus, these factors were the initial 
requirements for the classification of a protein as a SR protein (reviewed in Fu, 
1995). 
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Table 1.1: Conserved domains and features of RBBP6 proteins from select organisms 
ORGANISM REFSEQ 
ACCESSION 
PROTEIN LENGTH 
(A.A) 
MOLECULAR 
MASS (kDa) 
ISO-
ELECTRIC 
POINT 
DWNN ZINC 
FINGER 
(CCHC-
TYPE) 
ZINC 
FINGER-
LIKE 
SERINE-
RICH 
TRACT 
ARGININE-
RICH TRACT 
LYSINE-
RICH 
TRACT 
PROLINE-
RICH 
TRACT 
BIPARTITE 
NLS 
Homo sapiens NP_008841.2 RBBP6-1 1792 201.3 10.06 4-76 161-175 259-300 
(RING) 
682-772; 
1688-1726 
679-835 999-1788 337-410;  
548-608 
≤ 6 
Homo sapiens NP_061173.1 RBBP6-2 1758 197 10.05 4-76 161-175 259-300 
(RING) 
652-738; 
1654-1692 
672-801 965-1754 337-410;  
548-608 
≤ 6 
Homo sapiens NP_116015.2 RBBP6-3 118 13.2 9.13 4-76 - - - - - - - 
Mus musculus NP_035377.2 RBBP6-1 
(PACT)
#
 
1790 199.4 10.06 4-76 162-176 260-301 
(RING) 
683-773; 
1690-1726 
(376-405) 
680-836 1000-1784 338-411;  
549-609 
≤ 6 
Mus musculus NP_778188.1 RBBP6-2 123 13.8 9.11 4-76 - - - - - - - 
Mus musculus XM_006507470.1 RBBP6-3* 
(P2P-R)
#
 
1756 195.3 10.25 4-76 162-176 260-301 
(RING) 
653-739; 
1656-1692  
(376-405) 
673-802 966-1750 338-411;  
549-609 
≤ 6 
Drosophila 
melanogaster 
NP_611884.1 SNAMA-
PA 
1231 139 10.16 3-76 152-167 217-258 
(RING) 
- 562-647;  
998-1097 
805-848; 
1188-1231 
- ≤ 5 
Drosophila 
melanogaster 
NP_001246487.1 SNAMA-
PB 
494 55.6 6.3 3-76 152-167 217-258 
(RING) 
- - - - - 
Caenorhabditis 
elegans 
NP_001032975.1 RBPL-1 
isoform A 
1128 130.2 6.59 4-75 158-172 236-314 
 (U-box) 
498-517 
(1030-1072) 
479-609  
(891-967) 
765-1019 375-463 ≤ 14 
Caenorhabditis 
elegans 
NP_001032976.1 RBPL-1 
isoform B 
363 42.6 9.94 4-75 158-172 - (265-307) - 169-254 - ≤ 4 
Saccharomyces 
cerevisiae 
NP_012864.1 MPE1P 441 49.6 6.15 5-78 182-196 - - - - 402-425 - 
The locations of conserved structured, and unstructured, domains are shown for RBBP6 proteins, along with bio-physical properties. With the exception of H. sapiens, the animal species 
represented here are typical model organisms in which RBBP6 has been studied. * This protein is not yet officially recognized but is thought to exist. Numbers in parentheses represent low-
confidence predictions. NLS = nuclear localization signal.
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Proteins were also discovered which had an RS-domain but did not meet all the 
criteria of the previous paragraph. For example, modifications to the original 
precipitation technique, such as the addition of a phosphorylation step prior to 
precipitation (Blencowe et al., 1995), resulted in additional proteins co-purifying 
along with the six originally discovered SR proteins. The present criteria for the 
classification of a protein as a SR protein require that it must contain at least one 
amino-terminal RRM, and a downstream RS-domain which is at least 50 residues 
long and comprised of at least 40 % RS/SR dipeptides (Manley & Krainer, 2010). 
Simultaneously, the same authors also proposed renaming the resulting twelve 
proteins, which conformed to the new criteria, in line with HGNC convention. 
Thus, the twelve H. sapiens SR proteins are named SRSF1-12 (SR splicing 
factor), with all other RS-domain-containing proteins being unaffected by the 
naming convention and collectively referred to as SR-like proteins.   
 
The absence of an amino-terminal RRM therefore establishes some RBBP6 
proteins as SR-like proteins. Interestingly, SRSF7 (previously 9G8) also contains 
a CCHC-type zinc finger domain between its amino-terminal RRM domain and 
carboxyl-terminal RS-domain, although these two domains are distinctly different. 
The presence of the RS-domain therefore suggests that some RBBP6 proteins may 
be involved in activities such as mRNA processing, transcription and chromatin 
remodelling (Boucher et al., 2001). The activities of SR-like proteins are therefore 
similar to those of SR proteins, which are involved in all forms of mRNA 
processing (constitutive and alternative splicing, nuclear export, translation and 
degradation) (reviewed in Twyffels et al., 2011). In fact, the S. cerevisiae RBBP6 
protein, MPE1P, has been shown to be involved in mRNA processing (Vo et al., 
2001).  
 
Most RBBP6 proteins also contain at least one lysine-rich tract, which manifests 
in the form of multiple bipartite nuclear localization signals (NLS). These NLS 
are found scattered throughout the RS-domain and are in addition to the nuclear-
targeting sequences, comprising mostly arginine and serine residues, found to 
target RS-domain-containing proteins to nuclear speckles (Li & Bingham, 1991; 
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Hedley et al., 1995). Taken together, RBBP6 proteins are thought to localize to 
the nucleus, particularly nuclear speckles. As a result of these arginine-rich and 
lysine-rich tracts, most RBBP6 proteins also have very high isoelectric points, as 
arginine and lysine are, respectively, the two most basic amino acids.  
 
1.3 SNAMA  
 
The D. melanogaster RBBP6 homologue will be referred to by its first accorded 
name: Snama. Two Snama transcripts are known to exist. Snama-RA 
(FBtr0072249) was experimentally verified by both Northern blot analysis and 
reverse-transcription PCR (Mather, 2005; Mather et al., 2005; Jones et al., 2006). 
More recently, based on high-throughput sequencing data from Daines et al. 
(2011) which identified a splice junction in intron 7, Snama-RB (FBtr0307174) 
was predicted by FlyBase genome annotators. Interestingly, this transcript was 
visualized by Northern blot analysis after a longer period of exposure than was 
required to visualize Snama-RA (Jones et al., 2006), although it was not further 
explored as a second, possible Snama transcript. Consequently our group has 
unpublished data, generated via reverse-transcription PCR, verifying the existence 
of Snama-RB (Cajee, U.-F., in preparation).  
 
To date, no SNAMA proteins have been experimentally verified, despite 
immunological approaches undertaken in previous studies (Mather, 2005; Jones et 
al., 2006; Rakgotho, 2007; Hull, 2012). Snama-RA is predicted to encode a “full-
length” protein of 1231 amino acids (SNAMA-PA: FBpp0072158; 
NP_611884.1), whereas Snama-RB is predicted to encode a C-terminally 
truncated, alternatively-spliced variant of 494 amino acids (SNAMA-PB: 
FBpp0298003; NP_001246487.1). These two predicted proteins (Figure 1.4) are 
identical for the first 493 residues; the inclusion of intron 6-7 in Snama-RB results 
in the substitution of Ser
494
 with Arg
494
 which is immediately followed by a stop 
codon. These two putative proteins would manifest on a SDS-PAGE gel as 
proteins of 139 kDa (SNAMA-PA) and 55.6 kDa (SNAMA-PB).  
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Both predicted proteins contain a 258 residue long DCM, comprising the DWNN 
domain, CCHC-type zinc finger domain and zinc finger-like domain (Table 1.1 
and Figure 1.4). The D. melanogaster DWNN domain shares 23.5 % sequence 
homology with D. melanogaster ubiquitin (Mather, 2005; Mather et al., 2005), 
which is 5 % more than the H. sapiens counterparts. However, unlike in H. 
sapiens and M. musculus RBBP6 proteins, there is no di-glycine at the end of the 
DWNN domain. Moreover, given the absence of a stand-alone DWNN-domain 
protein in D. melanogaster, it seems unlikely that DWNNylation could occur in 
D. melanogaster, unless cleavage occurs on an uncharacterized recognition site 
and through an uncharacterized mechanism.  
 
The zinc finger-like domain of RBBP6 proteins differs from the canonical C3HC4 
sequence, as the fourth zinc-chelating residue is degenerate. In H. sapiens, M. 
musculus and C. elegans, the histidine has been replaced with an asparagine; 
whereas in D. melanogaster and S. cerevisiae, a serine and isoleucine are found, 
respectively. As the hydroxyl group of the serine is ionizable, it is thought that 
serine, in the D. melanogaster RING, can substitute for the sulfhydryl group of 
cysteines ordinarily involved in chelating zinc-ions (Mather, 2005). Recently, 
Ying et al. (2011) have classified RING domains found in D. melanogaster 
proteins into eight sub-divisions, of which the U-box domain is a member. 
Specific mention was made of SNAMA in that its RING domain was so 
uncommon, that it was grouped along with the “RING-G”-type, with a sequence 
of C3HGC3. To further complicate matters, Kappo et al. (2012) demonstrate that 
the H. sapiens RBBP6 RING domain is of the C4C4-type and not C3NC4 as was 
always thought to be the case. They further demonstrate, through NMR analysis, 
that the RING domain is stabilized by hydrogen bonding between backbone 
residues – as occurs in U-box domains, as well as through zinc-ion chelation – 
which is the hallmark of RING domains. Thus they suggest that the H. sapiens 
RBBP6 RING domain is an intermediary between classical RING and U-box 
domains. This view is supported by the work of Antunes (2008), in which 
SNAMA auto-ubiquitination was shown to occur both in the presence and 
absence of zinc-ions, in vitro. Furthermore, ScanProsite analysis classifies the C. 
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elegans zinc finger-like domain as a U-box (Table 1.1). Thus, uncertainty exists 
with regards to the classification of the SNAMA zinc finger-like domain: whether 
it is a C3SC4 RING, a C3HGC3 RING, a C4C4 RING, or a hybrid between a 
RING and U-box.  
 
Downstream of the DCM, there is a minor RS-domain common to both predicted 
SNAMA proteins, in which five RS-dipeptides are present. This 69 residue 
stretch, comprising residues 386-454, contains 24 serine and arginine residues. 
While SNAMA-PB terminates shortly after this region, this point represents only 
around one third of the SNAMA-PA sequence. The C-terminal two thirds of 
SNAMA-PA is highly enriched in SR/RS dipeptides. Of the 92 residues over the 
region 998-1089, 46 are arginine or serine, thus qualifying this region as a true 
RS-domain. SNAMA-PA also contains two lysine-rich tracts and five bipartite 
nuclear localisation signals. Combined, arginine and lysine residues account for 
over 20 % of the SNAMA-PA sequence, thus imparting SNAMA-PA with an 
extremely basic pI of 10.16 while SNAMA-PB, which lacks this C-terminal 
extension, has a pI of 6.74. Overall, the difference in the C-terminal domain, as 
well as the stark difference in pI, between SNAMA-PA and SNAMA-PB suggests 
that these two putative proteins localize to different cellular locations and may, 
possibly, also perform different biological functions.  
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Figure 1.4: Domains and features of putative SNAMA proteins. Sequence alignment between the 
two predicted SNAMA polypeptides demonstrates that SNAMA-PB is a C-terminally truncated, 
alternatively-spliced variant of SNAMA-PA. SNAMA-PB therefore lacks the C-terminal 
extension containing the RS-domain and various other features described in-text.  
 
 
SNAMA-PA 1     MSVHYKFKST LNFDTITFDG LHISVGDLKR EIVQQKRLGK IIDFDLQITN AQSKEEYKDD 
               |||||||||| |||||||||| |||||||||| |||||||||| |||||||||| |||||||||| 
SNAMA-PB 1     MSVHYKFKST LNFDTITFDG LHISVGDLKR EIVQQKRLGK IIDFDLQITN AQSKEEYKDD 
 
SNAMA-PA 61    GFLIPKNTTL IISRIPIAHP TKKGWEPPAA ENAFSAAPAK QDNFNMDLSK MQGTEEDKIQ 
               |||||||||| |||||||||| |||||||||| |||||||||| |||||||||| |||||||||| 
SNAMA-PB 61    GFLIPKNTTL IISRIPIAHP TKKGWEPPAA ENAFSAAPAK QDNFNMDLSK MQGTEEDKIQ 
 
SNAMA-PA 121   AMMMQSTVDY DPKTYHRIKG QSQVGEVPAS YRCNKCKKSG HWIKNCPFVG GKDQQEVKRN 
               |||||||||| |||||||||| |||||||||| |||||||||| |||||||||| |||||||||| 
SNAMA-PB 121   AMMMQSTVDY DPKTYHRIKG QSQVGEVPAS YRCNKCKKSG HWIKNCPFVG GKDQQEVKRN 
 
SNAMA-PA 181   TGIPRSFRDK PDAAENESAD FVLPAVQNQE IPEDLICGIC RDIFVDAVMI PCCGSSFCDD 
               |||||||||| |||||||||| |||||||||| |||||||||| |||||||||| |||||||||| 
SNAMA-PB 181   TGIPRSFRDK PDAAENESAD FVLPAVQNQE IPEDLICGIC RDIFVDAVMI PCCGSSFCDD 
 
SNAMA-PA 241   CVRTSLLESE DSECPDCKEK NCSPGSLIPN RFLRNSVNAF KNETGYNKSA AKPAAVKNEE 
               |||||||||| |||||||||| |||||||||| |||||||||| |||||||||| |||||||||| 
SNAMA-PB 241   CVRTSLLESE DSECPDCKEK NCSPGSLIPN RFLRNSVNAF KNETGYNKSA AKPAAVKNEE 
 
SNAMA-PA 301   KPPVEKEVEK KPVAEVEPEE TEVKPEKQKE SETNGSNPPK SESPEPPATT EPSQKEKDKY 
               |||||||||| |||||||||| |||||||||| |||||||||| |||||||||| |||||||||| 
SNAMA-PB 301   KPPVEKEVEK KPVAEVEPEE TEVKPEKQKE SETNGSNPPK SESPEPPATT EPSQKEKDKY 
 
SNAMA-PA 361   DSDYEDNITI KMPQPAADST TVPSKRSPSY SHRSESSHRR DRSDYVSDHD HKHQRPSKSE 
               |||||||||| |||||||||| |||||||||| |||||||||| |||||||||| |||||||||| 
SNAMA-PB 361   DSDYEDNITI KMPQPAADST TVPSKRSPSY SHRSESSHRR DRSDYVSDHD HKHQRPSKSE 
 
SNAMA-PA 421   SVNKDRSLLP LPIGTLPSYQ GHMMAESEEA RRSSAYKPPY MQMQRGPPPM HMMSHHMPAY 
               |||||||||| |||||||||| |||||||||| |||||||||| |||||||||| |||||||||| 
SNAMA-PB 421   SVNKDRSLLP LPIGTLPSYQ GHMMAESEEA RRSSAYKPPY MQMQRGPPPM HMMSHHMPAY 
 
SNAMA-PA 481   NNGFNNMGQR PPLSYVPYQN QSVHPMRAPY GSAGGGMNMN MSQPFQSPNL ASIYQGVAAK 
               |||||||||| |||.                                               
SNAMA-PB 481   NNGFNNMGQR PPLR 
 
SNAMA-PA 541   VGSGPIDDPL EAFNRIMKEK ERKKVDRFRS SDRHRSRSPD RQRHRFKSPM YEKDNSRDNL 
         601   KDKRPRSRER KREHSYERHI RHPRSSRQPN DGSKSPGGRI KRSGHRRSAS PKPGYKSDYR 
         661   DKPYNKPSAP KTEAVEPPPP GFEPLQLTDE DGYRNKHPTS SEASQSSKGD SSKKRGENRH 
         721   EEAPRKRHRS RSISKEPKPN DSNYRSLTPP AKITTPKMTA AQLRQRESSP KTPEKSHDDY 
         781   LTAKARIMAS QPVINDTEME TNVGKENKAK SPLSKDRKKK KKDKDKAERK KNKKDKRAKK 
         841   EKGDRQKKSS SVNRSDSDIN NSSLMNESNY KVLSPRAQSP SIEINAAQLS PTHNATENVN 
         901   PKSHSILTVG AASDDNLGPR SKLSEANSVN LSKWEIDENI LGLEDSSKKA AGASDDPSEI 
         961   TSDVLRKAEN AIFAKAINAI RPMEFQVIIN SKDNSKDRSV VRSDKDRSSS PRRNNSSRSV 
         1021  KDRLGTKISN DRSRSRDKSK GRRRAARSSD DDANRGRSDR HGSRKRDNRS RDRAAPSEKR 
         1081  QERSYKRSSP EDDKLRRQNK EQSESKHGKH DQNNSDDSDR RAAKNTKSSD SRVVSSVTAV 
         1141  VAPPKPCRPD NPFRKFVDTS SSSSLVVKYD NTIQKEGASS DNGMEHRKQR DKKLKKHSKY 
         1201  SSTDSLKSEK RKDPKSKKKS KILKKKKKSK K 
 
DWNN domain     RS/SR dipeptides 
CCHC-type Zinc finger domain   Bipartite Nuclear Localization Signal 
RING-type finger-like domain    
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1.4 RBBP6 FUNCTIONS AND INTERACTING PROTEINS 
 
RBBP6 proteins are known to function in a wide range of processes. When the 
first RBBP6 protein, RBQ, was discovered, interest was mostly focussed on the 
role played by RBBP6 proteins in cell-cycle control. RBBP6 null mutations have 
been shown to be lethal (Vo et al., 2001; Mather, 2005; Mather et al., 2005; Li et 
al., 2007; Huang et al., 2013) with effects such as p53 accumulation and altered 
cell-cycle profiles, such as polyploidy, manifesting (Jones et al., 2006; Huang et 
al., 2013). These effects were due, in part, to the fact that both H. sapiens and M. 
musculus RBBP6 proteins were shown to bind Rb (Saijo et al., 1995; Sakai et al., 
1995; Simons et al., 1997; Witte & Scott, 1997) and p53 (Simons et al., 1997; 
Gao et al., 2002) tumour suppressor proteins. Surprisingly, only mammalian 
RBBP6 proteins have Rb and p53 binding domains (Pugh et al., 2006).  
 
RBBP6 proteins have been shown to be highly expressed in testis and / or oocytes 
(Simons et al., 1997; Yoshitake et al., 2004; Mather, 2005; Huang et al., 2013) as 
well as intestine (Huang et al., 2013). Expression of RBBP6 proteins is highest in 
proliferating tissues and lowest in differentiated cells (Witte & Scott, 1997; Jones 
et al., 2006). RBBP6 has a role to play in transcription-related activities as 
RBBP6 forms part of the estrogen-transcription complex (Peidis et al., 2010) and 
localizes to nuclear speckles (Gao & Scott 2002; Scott et al., 2003; Huang et al., 
2013). Further RBBP6 activities occurring in nuclear speckles include mRNA 
processing (Vo et al., 2001), specifically as a component of the Yeast Cleavage 
and Polyadenylation Factor (CPF). These nuclear-related activities likely involve 
the RS-domain of RBBP6 proteins. 
 
More recently, attention has shifted towards a role for RBBP6 proteins in protein 
quality control (Li et al., 2007; Antunes, 2008; Chibi et al., 2008; Kappo et al., 
2012). RBBP6 has been shown to facilitate HDM2-mediated ubiquitination of p53 
(Li et al., 2007), thereby suggesting one mechanism in which mammalian RBBP6 
proteins interact with tumour suppressors to regulate cell cycle control. HDM2-
mediated ubiquitination occurred independently of a functional RING domain 
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thus suggesting that RBBP6 acts as an E4 enzyme (Li et al., 2007). RBBP6 
proteins have been shown to possess E3 ubiquitin ligase activity: Chibi et al. 
(2008) demonstrated that RBBP6 could bind Y-box binding protein 1 (YB-1) 
through its RING finger-like motif, in vivo. They went on further to demonstrate 
that YB-1 was subsequently ubiquitinated and degraded via the proteasome. 
Furthermore, Antunes (2008) demonstrated auto-ubiquitination of the SNAMA 
DCM, in vitro. As mentioned previously, although RBBP6 proteins are identified 
by an N-terminal DWNN domain which is thought to be a putative form of 
ubiquitin-like modification, DWNNylation remains unproven. Although the 
ubiquitin-related activities described in this paragraph are more reliant on the 
DCM than the unstructured domains of the C-terminus, RBBP6 proteins likely 
have multiple roles within a cell. Known binding partners of RBBP6 proteins are 
presented in Table 1.2, with numerous others possibly awaiting discovery. 
 
Table 1.2: Experimentally verified protein interaction partners of RBBP6 proteins  
BINDING PROTEIN REFERENCE 
RB (Retinoblastoma) Saijo et al., 1995; Sakai et al., 1995; Simons 
et al., 1997; Witte & Scott, 1997 
P53 Li et al., 2007; Simons et al., 1997 
HDM2 (Human-double-minute 2) Li et al., 2007 
YB-1 (Y-box binding protein 1) Chibi et al., 2008 
Cdc2 Scott et al., 2003 
SAF-B (scaffold attachment 
factor – B) 
Scott et al., 2003 
Nucleolin Scott et al., 2003 
SRPK1/ SRSF (SR-rich splicing 
factor protein kinase) 
Scott et al., 2003 
ERα (Estrogen receptor alpha) Peidis et al., 2010 
SRC-1 (steroid receptor co-
activator 1) 
Peidis et al., 2010 
The few proteins listed here represent only experimentally verified, direct interaction partners of 
RBBP6 proteins. These proteins are mostly involved in activities centred on cell-cycle control and 
gene transcription.  
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1.5 AIMS AND OBJECTIVES 
 
The primary aim of this study was to characterize the RBBP6 family of proteins in 
Drosophila melanogaster and to test the hypothesis that SNAMA may be 
involved in apoptosis in a p53-dependant manner. 
 
The specific objectives of this study were to: 
 Heterologously express and purify a fusion protein comprised of the 
SNAMA DCM fused to the GST and HIS expression tags of pET41a(+) 
vector. This objective also requires the expression and purification of a 
negative control protein, which is comprised of only the expression tags of 
the pET41a(+) vector. 
 Prepare and purify chicken antibodies raised against the SNAMA DCM 
protein. 
 Determine, through Western blot analysis, the number of SNAMA 
isoforms as well as their spatio-temporal regulation. 
 Identify, through co-immunoprecipitation assays, potential interaction 
partners of SNAMA proteins. 
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CHAPTER TWO 
 
2. MATERIALS AND METHODS 
 
All chemicals utilized in this project were, unless otherwise stated, purchased 
from either Sigma-Aldrich or Merck Biosciences.  
 
2.1 KITS 
 
Table 2.1: Commercial kits or kit components utilized throughout this study 
DESCRIPTION SUPPLIER CATALOGUE 
NUMBER 
Aldehyde-agarose Sigma-Aldrich A9951 
Anti-Chicken IgY Peroxidase 
conjugate 
Sigma-Aldrich A9046 
Bio-Rad protein assay Bio-Rad 500-001 
BioMax
®
 light film Sigma-Aldrich Z373508 
Chicken IgY Precipitating Resin GenScript L00405 
Chromatography columns       
30 ml (Econo-Pac) 
Bio-Rad 732-1010 
DNAse Sigma-Aldrich AMP-D1 
Glutathione-Agarose Sigma-Aldrich G4510 
HIS-Select
®
 Nickel Affinity Gel Sigma-Aldrich P6611 
PageRuler™Prestained Protein 
Ladder* 
Fermentas Life Sciences SM0671 
Polyscreen PVDF transfer 
membrane 
Perkin Elmer Life Sciences, 
Inc 
NEF1002 
Protease Inhibitor Cocktail Set 
II 
Calbiochem (Merck 
Biosciences) 
539132 
SnakeSkin™ Pleated Dialysis 
Tubing 
Thermo Scientific 68035 
Stirred cell ultrafiltration unit, 
model 8003 
Amicon Merck 5125 
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Stirred cell ultrafiltration filters, 
NMWL 10000 
Amicon Merck PLGC02510 
Sodium cyanoborohydride,        
5 M solution in aqueous 1 M 
sodium hydroxide 
Sigma-Aldrich 296945 
SuperBlock
®
 Dry Blend 
Blocking Buffer in TBS 
Pierce 37545 
SuperSignal
®
 West Pico 
Chemiluminescent Substrate Kit 
Pierce 34080 
* See Figure A1 for band sizes of the PageRuler™ molecular weight marker. 
 
2.2 BACTERIAL STRAIN AND VECTOR 
 
Table 2.2: Vector and bacterial strain utilized in this study 
VECTOR / 
BACTERIA 
STRAIN ANTIBIOTIC 
RESISTANCE 
SUPPLIER CATA-
LOGUE  
NUMBER 
pET-41a(+)* Not applicable Kanamycin Novagen 
(Merck 
Biosciences) 
70556-3 
Escherichia 
coli BL21 
(DE3) pLysS 
F- ompT hsdSB 
(rB - mB-) gal 
dcm (DE3) 
pLysS (Cam
R
) 
Chloramphenicol Invitrogen C6060-10 
* See Figure B1 for an overview of the various features of the pET-41a(+) expression vector. 
 
2.3 MEDIA 
 
Table 2.3: Composition of media utilized in organism maintenance and growth 
MEDIA COMPOSITION  
Apple juice agar plates 5 % sucrose; 8 % agar; 25 % apple juice;  
0.6 % methyl paraben; 0.1 % Streptomycin 
Cornmeal molasses 1 % sucrose; 1.05 % agar; 3 % cornmeal;  
5 % molasses 2 % dry yeast; 0.15 % methyl paraben 
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Luria-Bertani (LB) agar 
plates 
1 % tryptone; 0.5 % yeast extract;  
1 % sodium chloride; 1.5 % agar 
LB broth 1 % tryptone; 0.5 % yeast extract;  
1 % sodium chloride 
 
2.4 MAINTENANCE OF RESEARCH ORGANISMS 
 
2.4.1 Maintenance of bacterial clones 
Bacterial clones utilized in this project were maintained on LB agar plates 
containing 30 µg/ml Kanamycin and 100 µg/ml Chloramphenicol. Plates were 
restreaked every three weeks. 
 
2.4.2 Maintenance of Drosophila melanogaster 
 Wild-type (Oregon-R) flies, reared at 25 ºC, were utilized in this study. The stock 
fly strain was maintained in cornmeal molasses vials, changed weekly. The vials 
were supplemented with fresh yeast prior to transfer of flies. For experiments, 
however, between 5000 and 10000 adult flies were housed in a cage and provided 
with apple juice agar plates containing fresh yeast spread on the surface of the 
plate. Plates were changed every 12 hours during maintenance, or alternatively, as 
stipulated when collecting embryos for experiments. In experiments requiring 
stages of development post-embryo stage, the embryos were transferred to 
cornmeal molasses media to allow for further development. 
 
2.5 GENERAL MOLECULAR BIOLOGY METHODS 
 
The methodologies described – and buffers listed – in this section, are common 
molecular biology techniques which were performed in multiple experiments of 
this study. Sections 2.6-2.9 detail more specific methodologies, and buffer 
components, pertaining to the specific investigation.  
 
2.5.1 General buffers and solutions  
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Table 2.4: General buffers and solutions utilized in various experiments throughout this study 
BUFFER / SOLUTION COMPOSITION 
Immobilized metal-ion affinity chromatography 
IMAC cleansing buffer 50 mM sodium phosphate buffer, pH 8.0;  
6 M guanidine hydrochloride 
IMAC elution buffer 50 mM sodium phosphate buffer, pH 6.5;  
0.1 M NaCl; 8 M urea; 350 mM imidazole 
IMAC equilibration buffer 50 mM sodium phosphate buffer, pH 8.0;  
0.1 M NaCl; 8 M urea 
IMAC wash buffer 50 mM sodium phosphate buffer, pH 6.5;  
0.1 M NaCl; 8 M urea 
Glutathione affinity chromatography 
GSH cleansing buffer 1 0.1 M borate buffer, pH 8.5; 0.5 M NaCl 
GSH cleansing buffer 2 0.1 M acetate buffer, pH 4.5; 0.5 M NaCl 
GSH elution buffer 0.1 M sodium phosphate buffer, pH 8.0; 
0.1 M NaCl; 15 mM reduced-glutathione 
GSH wash buffer 0.1 M sodium phosphate buffer, pH 8.0;  
0.1 M NaCl; 0.1 % Triton™ X-100 
SDS-PAGE 
SDS-PAGE electrode running 
buffer (5X) 
125 mM Tris base; 1 M glycine; 17 mM SDS;  
pH 8.2 
SDS-PAGE sample buffer 
(5X) 
0.313 M Tris-HCl, pH 6.8; 10 % glycerol;  
2 % SDS; 5 % β-mercaptoethanol;  
0.05 % bromophenol blue 
SDS-PAGE separating layer 0.375 M Tris-HCl, pH 8.8; 3.5 mM SDS;  
12 % (37.5:1) acrylamide/bis-acrylamide;  
2.2 mM ammonium persulphate; 0.1 % TEMED 
SDS-PAGE stacking layer 62.5 mM Tris-HCl, pH 6.8; 3.5 mM SDS;  
4 % (37.5:1) acrylamide/bis-acrylamide;  
4.4 mM ammonium persulphate; 0.2 % TEMED 
Gel staining and destaining 
Coomassie brilliant blue 
staining solution 
0.1 % Coomassie blue R-250; 40 % ethanol;  
10 % glacial acetic acid; 50 % ddH20 
Destain solution 40 % ethanol; 10 % glacial acetic acid;  
50 % ddH20 
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Silver stain developer 2 % Na2CO3; 0.02 % formalin 
Silver stain fixative 30 % ethanol; 10 % glacial acetic acid 
Silver stain sensitizer solution 0.02 % sodium thiosulphate 
Silver stain staining solution 0.1 % silver nitrate 
Silver stain wash solution 20 % ethanol  
Immunoblotting 
PVDF membrane wash buffer 1X PBS buffer, pH 7.4; 0.1 % Tween
®
20 
Towbin buffer 25 mM Tris base; 192 mM glycine; 0.1 % SDS;  
20 % methanol; pH 8.2 
 
Generic 
Chromatography column 
storage buffer 
50 mM Tris-HCl, pH 7.5; 0.1 M NaCl;  
1mM NaN3 
PBS buffer (10X) 1.4 M NaCl; 27 mM KCl; 0.1 M Na2HPO4;  
18 mM KH2PO4; pH 7.4 
 
2.5.2 Purification of tagged proteins 
Column affinity chromatography was used to purify recombinantly-expressed 
proteins produced in this study. All parts of the procedure in which sample was 
present were performed under gravity, while a peristaltic pump was used at all 
other times. Prepared columns were preserved in chromatography column storage 
buffer between experiments.  
  
2.5.2.1 Immobilized metal-ion affinity chromatography 
A 30 ml chromatography column, containing 2 ml of HIS-Select
®
 nickel affinity 
gel, was prepared according to the manufacturers’ instructions. Purification of 
SNAMA DCM protein via its two HIS-tags was performed according to the resin 
manufacturer’s instructions. 
 
2.5.2.2 Glutathione affinity chromatography 
A 30 ml chromatography column, containing 1 ml of Glutathione-Agarose was 
prepared according to the manufacturers’ instructions. Purification of GST-tagged 
proteins was performed according to the resin manufacturer’s instructions.  
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2.5.3 Protein concentration 
Samples were concentrated via stirred-cell ultrafiltration, using filters with a 
MWCO of 10 kDa, according to the manufacturer’s instructions.  
 
2.5.4 Protein quantification 
Protein concentration was determined via the Bio-Rad protein assay according to 
the manufacturer’s instructions.  
 
2.5.5 Sodium dodecyl sulphate – polyacrylamide gel electrophoresis 
The denaturing, discontinuous gel method of Laemmli (1970) was followed, 
consisting of 12 % separating and 4 % stacking layers. Samples were boiled in 1 
X SDS-PAGE sample buffer for 5 minutes prior to loading. Unless otherwise 
stated, 10 µg of protein, as determined in Section 2.5.4 prior to SDS-PAGE 
analysis, was loaded per lane. PageRuler
®
 Prestained protein ladder was added to 
all gels for size comparison. Electrophoresis was performed at a constant voltage 
of 100 V.  
 
2.5.6 Coomassie brilliant blue staining and destaining 
Polyacrylamide gels were stained overnight in Coomassie brilliant blue staining 
solution and destained, the following morning, in destain solution until desired.  
 
2.5.7 Silver staining 
Silver staining was performed according to the MS-compatible methodology of 
Shevchenko et al. (1996).  
 
2.5.8 Immunoblotting 
Following SDS-PAGE separation, samples were transferred to Polyscreen
®
 PVDF 
membrane using Towbin buffer (Towbin et al., 1979) at a constant current of 295 
mA for 90 minutes. The membrane was placed in SuperBlock
®
 blocking buffer 
for at least one hour at 4 ºC before being subjected to three successive, 40 ml 
changes of PVDF membrane wash buffer for 10 minutes at a time. The membrane 
was probed for one hour with a 1: 40000 primary antibody dilution; this equated 
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to a total of 0.45 µg of anti-SNAMA DCM antibody, or alternatively, 3.16 µg of 
pre-immune serum which was used as a negative control probe. The membrane 
was washed thrice each time after exposure to primary and secondary antibodies. 
Anti-Chicken IgY Peroxidase conjugate was used as a secondary antibody, at a 
dilution of 1: 60000. SuperSignal
®
 Chemiluminescent substrate kit was utilized 
for signal generation, which was captured on BioMax
®
 light film.   
 
2.5.9 Analysis of gels and films 
All gels and films were scanned on a Bio-Rad GS800 calibrated densitometer (cat. 
no. 170-7980). Analysis, such as detection of bands and determination of band 
sizes, was performed using the accompanying Quantity One
®
 software.  
 
2.6 EXPRESSION, EXTRACTION AND REFOLDING OF SNAMA DCM 
PROTEIN 
 
SNAMA DCM protein was prepared in order to perform pulldown assays, with a 
view towards investigating the biological functions of RBBP6 proteins in 
Drosophila.  
 
Table 2.5: Buffers and solutions used in refolding experiments 
BUFFER/SOLUTION COMPOSITION 
Protein extraction and inclusion body treatment 
Bacteria lysis buffer 1 50 mM Tris-HCl, pH 7.5; 2 mM EDTA, pH 
7.5; 200 mM NaCl; 0.1 mM PMSF;  
200 µg/ml lysozyme 
Inclusion body solubilisation 
buffer 1 
50 mM sodium phosphate buffer, pH 8.0;  
8 M urea; 0.1 M NaCl; 1 mM PMSF;  
2 mM DTT 
Inclusion body wash buffer 1 50 mM Tris-HCl, pH 7.5; 2 mM EDTA, pH 
7.5; 200 mM NaCl; 0.1 mM PMSF;  
1 % Triton™ X-100 
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Refolding of SNAMA DCM protein via dialysis 
Dialysis buffer 1 (No additives) 50 mM sodium phosphate buffer, pH 8.0;  
0.1 M NaCl 
Dialysis buffer 2 (With 
additives) 
50 mM sodium phosphate buffer, pH 8.0;  
0.1 M NaCl; 5 mM EDTA;  
5 mM β-cyclodextrin; 50 mM arginine 
Dialysis buffer 3 (Redox) 50 mM sodium phosphate buffer, pH 8.0;  
0.1 M NaCl; 5 mM β-cyclodextrin;  
50 mM arginine; 0.1 mM ZnCl2;  
1 mM reduced glutathione;  
0.3 mM oxidized glutathione 
 
2.6.1 Revival of bacterial clones from glycerol stocks and protein expression 
The “control” and “SNAMA DCM” bacterial clones utilized throughout this study 
were prepared by a former colleague (Antunes, 2008). This project was begun by 
reviving glycerol stocks of the two aforementioned bacterial clones, which were 
thereafter maintained on LB agar plates. For protein expression, a 2 ml starter 
culture of LB broth was inoculated with the required bacterial clone, which was 
then incubated overnight at 37 ºC with orbital rotation of 250 revolutions per 
minute. The following day, the 2 ml starter culture was transferred to a two litre 
Erlenmeyer flask containing 500 ml LB broth supplemented with 10 µg/ml 
Kanamycin. Cells were grown to an O.D600 of between 0.5 and 0.6 before protein 
expression was induced via the addition of IPTG to a concentration of 0.2 mM. 
Induction lasted for 5 hours, after which the culture was aliquoted into 
polypropylene tubes and centrifuged at 1500 x g for 10 minutes at 4 ºC. After 
removal of the LB broth supernatant, bacterial pellets were frozen at -20 ºC until 
further processed.   
 
 2.6.2 Protein extraction and inclusion body treatment  
Thawed cells, prepared as described in Section 2.6.1, were resuspended in bacteria 
lysis buffer 1 in a ratio of 10 ml lysis buffer per 100 ml original culture volume. 
The extract was maintained on ice for the entire protein extraction procedure. 
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Three microlitres of DNAse was added to the extract which was then subjected to 
mild sonication until all cellular components were solubilized. After a one hour 
incubation period with brief, periodic agitation, the extract was centrifuged at 
11000 x g for 10 minutes at 4 ºC after which the supernatant was discarded.  
 
The resultant pellet fraction was resuspended in inclusion body wash buffer 1, in a 
volume equal to that used of bacterial cell lysis buffer 1, and subjected to end-
over-end mixing for 15 minutes. The suspension was centrifuged at 8000 x g, for 
10 minutes at 4 ºC, after which the supernatant was discarded. These steps were 
repeated once more, before resuspending the inclusion bodies in a 1-in-2 dilution 
of inclusion body wash buffer 1, with subsequent steps repeated. The treated 
inclusion body mass was then resuspended overnight, at 4 ºC via end-over-end 
mixing, in 5 ml of inclusion body solubilisation buffer 1, followed the next 
morning by clarification at 11000 x g for 15 minutes at 4 ºC. The inclusion bodies 
were then subjected to immobilized metal-ion affinity chromatography, to further 
select for SNAMA DCM protein. 
 
2.6.3 Refolding of SNAMA DCM protein via dialysis 
Refolding via dialysis was performed according to the two methodologies [(i) and 
(ii) below] reported in Antunes (2008) as yielding correctly refolded SNAMA 
DCM protein. Further attempts [(iii) below] were made at refolding the SNAMA 
DCM protein using experimental approaches based on literature available at 
REFOLD (Chow et al., 2006). In all instances, approximately 5 ml of IMAC-
purified SNAMA DCM protein (Section 2.6.2) was placed in SnakeSkin™ 
pleated dialysis tubing and subjected to one of the procedures detailed below. 
Dialysis was performed at 4 ºC overnight; a magnetic stirrer bar was utilized to 
facilitate diffusion. 
 
(i) Dialysis without additives 
The sample was subjected to a one-step, 100-fold volume of dialysis buffer 1. 
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(ii) Dialysis with additives 
The sample was subjected to a one-step, 100-fold volume of dialysis buffer 2. 
 
(iii) Dialysis with redox buffer 
The sample was subjected, for 4 hours at a time, to 3 sequential changes of 
dialysis buffer 3, in which the first buffer was supplemented with 4 M urea, the 
second buffer with 2 M urea, while the final buffer lacked urea. The sample was 
then dialyzed overnight in a fourth change of dialysis buffer 3. In each buffer, the 
dialysate was 100 times the volume of sample. 
 
2.6.4 Recovery of correctly-refolded SNAMA DCM protein 
Dialyzed samples were clarified by centrifugation at 10000 x g for 10 minutes at 4 
ºC prior to being processed via glutathione affinity chromatography. The 
standardized manufacturer’s instructions were mostly followed, with two 
exceptions: resins were equilibrated, and bound proteins washed, with the relevant 
dialysate used in the refolding attempt. The fractions generated were then 
analyzed via SDS-PAGE.  
 
2.7 PREPARATION AND PURIFICATION OF ANTI-SNAMA DCM 
ANTIBODIES FROM CHICKEN SERUM 
 
Anti-SNAMA DCM antibodies were sought in order to verify the existence of the 
two putative SNAMA proteins via immunoblotting and form the backbone of 
further experimental approaches in this study.  
 
Table 2.6: Buffers and solutions used in the preparation and purification of anti-SNAMA DCM 
antibodies 
BUFFER/SOLUTION COMPOSITION 
Protein extraction and inclusion body preparation 
Bacteria lysis buffer 2 0.1 M sodium phosphate buffer, pH 7.4;  
0.15 M NaCl; 0.2 % Triton™ X-100;  
100 µg/ml lysozyme 
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Inclusion body solubilisation 
buffer 2 
50 mM sodium phosphate buffer, pH 7.4;  
0.1 M NaCl 
Inclusion body wash buffer 2 0.1 M sodium phosphate buffer, pH 7.4;  
1.5 M NaCl; 0.5 M urea; 2 % Triton™ X-100 
Cross-linking of control proteins to aldehyde-agarose 
Blocking buffer 0.1 M Tris-HCl, pH 8.8 
Reducing agent Sodium cyanoborohydride, 5 M solution in 
aqueous 1 M sodium hydroxide – see Table 2.1 
Resin equilibration buffer 50 mM sodium phosphate buffer, pH 7.4;  
0.1 M NaCl 
Purification of anti-SNAMA DCM antibodies 
Antibody elution buffer 0.1 M glycine-HCl, pH 3.0 
Antibody neutralization buffer 1 ml of 1X PBS buffer, pH 7.4;  
100 µl of 1 M Na2HPO4, pH 8.8 
Antibody purification buffer   1X PBS buffer, pH 7.4; 0.1 % Tween®20 
 
2.7.1 Preparation of immunogen 
SNAMA DCM protein was prepared as described in Sections 2.6.2 and 2.6.3. 
Prepared protein was concentrated to 200 µg/ml via stirred cell ultrafiltration and 
provided to Professor Theresa Coetzer, of the University of KwaZulu-Natal, for 
polyclonal antibody proliferation in adult chickens. As the author was not 
involved in any further procedures related to antibody production (e.g., injection 
of immunogen and adjuvant, bleeds, etc.), this falls outside the scope of this 
project and is not described. 
 
2.7.2 Preparation of control proteins for use in antibody purification and as 
controls in immunoblotting. 
 
2.7.2.1 Positive control 
Pelleted SNAMA DCM cells were prepared as described in Section 2.6.1. Thawed 
cells were lysed in 5 ml bacteria lysis buffer 2 per 100 ml original culture volume, 
along with gentle sonication. Three microlitres of DNAse was added per 5ml 
extract, which was placed on ice for a further hour. After centrifugation at 10000 
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x g for 10 minutes, the supernatant was discarded and the inclusion body mass 
resuspended, via gentle pipetting, in 1 ml inclusion body wash buffer 2 per 5 ml 
original protein extract. The sample was centrifuged at 500 x g for 5 minutes 
before repeating the wash and low speed centrifugation steps twice more.  
 
The previous resuspension and low speed centrifugation steps were repeated a 
further three times using 1ml inclusion body solubilisation buffer 2, although this 
was effectively a wash to remove residual compounds such as urea which would 
interfere with cross-linking. The inclusion body mass was re-suspended a final 
time, via gentle pipetting, in 1 ml inclusion body solubilisation buffer 2 and 
subjected to end-over-end mixing, overnight, at 4 ºC. Following clarification at 
3000 x g for 10 minutes, the supernatant was transferred to a new tube and the 
protein concentration determined via the Bio-Rad protein assay. Sample to be 
cross-linked to aldehyde-agarose was utilized immediately, whereas sample 
destined for use as a positive control in immunoblots was made up to 30 % with 
glycerol and stored at -30 ºC.  
 
2.7.2.2 Negative control 
Pelleted control cells were prepared as described in Section 2.6.1. Thawed cells 
were lysed in 5 ml bacteria lysis buffer 2 per 100 ml original culture volume, 
along with gentle sonication. Three microlitres of DNAse was added per 5ml 
extract, which was placed on ice for a further hour. The extract was centrifuged at 
3000 x g for 10 minutes and the supernatant transferred to a new tube. Protein 
concentration was determined via the Bio-Rad protein assay. Sample to be cross-
linked to aldehyde-agarose was utilized immediately. However, for sample to be 
used as a negative control in immunoblots, glycerol was added to 30 % before 
storage at -30 ºC.  
 
2.7.3 Cross-linking of control proteins to aldehyde-agarose 
Two 30 ml chromatography columns, each containing 1 ml of aldehyde-agarose, 
were prepared according to the manufacturers’ instructions. Cross-linking of 
control proteins to their respective resins was performed according to the resin 
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manufacturer’s instructions. In total, 4.5 mg of positive control protein extract was 
cross-linked to the positive control resin, while 6.5 mg of negative control protein 
extract along with 2 mg dialyzed, glutathione affinity purified control protein was 
cross-linked to the negative control resin.  
 
2.7.4 Selection of anti-SNAMA DCM antibodies from post-immune serum 
The positive control column, containing a frit only below the resin, was 
equilibrated with antibody purification buffer and thereafter plugged at the 
drainage spout. The resin was resuspended, through gentle vortexing, in a 2 ml 
solution consisting of 1 ml post-immune serum and 1 ml antibody purification 
buffer. The resin was allowed to settle before gently resuspending it once more. 
Resuspension was repeated several times, at random, over a three hour period, 
after which the column was drained of the serum solution.  
 
The column was again plugged and the resin resuspended in 2 ml antibody 
purification buffer, which was drained as soon as the resin had settled. This wash 
procedure was repeated a further four times. Thereafter, the resin was resuspended 
in 1 ml of antibody elution buffer which was drained, as soon as the resin had 
settled, into a 15 ml tube containing 1.1 ml of antibody neutralization buffer. This 
was immediately followed by resuspending the resin in 1 ml of antibody 
purification buffer, which was then also drained into the same 15 ml tube as soon 
as the resin had settled. The eluted antibody fraction was further processed via 
pre-adsorption (Section 2.7.5) whereas the positive control column was cleaned 
with GSH cleansing buffers 1 & 2 and stored in chromatography column storage 
buffer for future use. 
 
2.7.5 Adsorption of contaminating antibodies from partially purified anti-
SNAMA DCM antibody solution as well as the pre-immune serum 
The negative control column was equilibrated in antibody purification buffer, 
after which the drainage spout was sealed. The resin was resuspended, via gentle 
vortexing, in either the partially purified anti-SNAMA DCM antibody solution 
(Section 2.7.4), or pre-immune serum diluted in an equal volume of antibody 
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purification buffer, and allowed to settle. Resuspension was performed at random 
and repeated several times over a two hour period, after which the pre-adsorbed 
antibody (anti-SNAMA DCM or pre-immune serum) was drained from the 
column. The negative control column was stripped of adsorbed antibodies through 
use of GSH cleansing buffers 1 & 2, after which the column was either 
equilibrated for a second round of pre-adsorption of the recently drained antibody 
solution, or else stored in chromatography column storage buffer between use. 
The protein concentration of the purified antibody (either SNAMA DCM or pre-
immune serum) was determined via the Bio-Rad protein assay, after which 
glycerol was added to 30 %; a working aliquot was stored at 4 ºC with remaining 
aliquots stored at -30 ºC.  
 
2.7.6 MALDI-TOF confirmation of anti-SNAMA DCM antibody specificity 
Positive control protein was separated via SDS-PAGE and stained with 
Coomassie brilliant blue stain. The 63 kDa SNAMA DCM band, as determined 
via scanning densitometry, was excised from the gel and transferred to a tube 
containing 5 % acetic acid solution. Further preparation steps, as well as MALDI-
TOF sequencing and analysis, were performed by the Plateforme Protéomique, 
Université de Strasbourg, Institut de Biologie Moléculaire et Cellulaire, 
Strasbourg, France. See Figure E1 for sequencing results. 
 
2.8 INVESTIGATION OF THE SPATIO-TEMPORAL REGULATION OF 
SNAMA PROTEINS 
 
Immunoblotting was performed in order to determine the stages in the Drosophila 
life-cycle, as well as the likely cellular compartments, in which SNAMA proteins 
are functional. 
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Table 2.7: Buffers and solutions used in investigating the spatio-temporal expression of SNAMA 
proteins 
BUFFER/SOLUTION COMPOSITION 
Subcellular fractionation of 0-6 hour old embryos 
Embryo grinding buffer 15 mM HEPES-KOH, pH 7.4; 10 mM KCl;  
0.2 mM EDTA; 1 mM DTT; 0.35 M sucrose;  
1 µl/ml Protease inhibitor cocktail 
Embryo wash solution 0.7 % NaCl; 0.05 % Triton™ X-100 
Organelle solubilisation buffer 50 mM HEPES-KOH, pH 7.4; 100 mM KCl;  
0.2 mM EDTA; 1 mM DTT;  
0.05 % Triton™ X-100;  
1 µl/ml Protease inhibitor cocktail;  
1 µl/ml DNAse 
In vitro modification of protein extracts 
Acetylation 50 % sample to be acetylated;  
25 % 25 mM NaHCO3, pH 8.0;  
25 % 10 µg/ml acetyl N-hydroxysuccinamide 
ester in N,N-dimethylformamide 
Phosphorylation 1 ml sample to be phosphorylated;  
16 µl 0.1 M ATP;  
10 µl 0.5 M creatine phosphate 
Mg
2+
-precipitation 20 µl 1 M MgCl2 
Exposure of flies to camptothecin as a means of up-regulating Snama 
Camptothecin treatment 1 mM camptothecin dissolved in dimethyl 
sulfoxide 
 
2.8.1 Classification and preparation of samples according to age 
Protein extracts were prepared from commonly classified morphological stages of 
development covering the entire Drosophila life cycle. The number of hours of 
development for each morphological stage, post-deposition of an egg on an apple 
juice agar plate, was in accordance with Strickberger (1962). All samples were 
prepared by homogenizing 30 mg of organism, from a relevant stage of 
development, in 200 µl of 5 X SDS-PAGE sample buffer. The extract was 
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clarified by centrifugation at 10000 x g, after which the supernatant was 
transferred to a new tube and boiled at 95 ºC for 5 minutes. As SDS renders 
protein quantification impractical, ten microlitres of prepared sample was 
separated via SDS-PAGE and analyzed via immunoblotting.   
 
2.8.2 Subcellular fractionation of 0-6 hour old embryos via differential 
velocity centrifugation 
Zero to six hour old embryos were fractionated based on the methodology of Tie 
et al. (2001), with modifications. Briefly, embryos were dechorionated using 
household bleach and rinsed twice thereafter: first with embryo wash, followed by 
ddH2O. The embryos were homogenized in an eppendorf tube with a plastic pestle 
in 0.5 ml embryo grinding buffer per 200 mg dechorionated embryos. The extract 
was centrifuged at 1000 x g, at 4 ºC, for 10 minutes, after which both the 
supernatant fraction and pelleted nuclei were extracted to separate tubes.  
 
The nuclei were resuspended in ice-cold organelle solubilisation buffer in a 
volume equal to that used of embryo grinding buffer and further homogenized 
using a dounce homogenizer. The now solubilized nuclei represent the nuclear 
fraction. 
 
The supernatant fraction was centrifuged at 1000 x g, for 5 minutes, at 4 ºC and 
transferred to a new tube. This procedure was repeated a further three times in 
order to discard floating lipid contaminants as well as to ensure complete removal 
of cellular debris and potentially remaining nuclei. The supernatant was 
centrifuged at 18000 x g for 30 minutes at 4 ºC and transferred to a new tube. This 
supernatant fraction represents the soluble cytosolic fraction. The pellet resulting 
from the 18000 x g centrifugation step was resuspended and homogenized exactly 
as was done with pelleted nuclei and represents the post-nuclear fraction. This 
fraction is expected to contain organelles such as ribosomes, endoplasmic reticuli 
and Golgi apparati. The protein concentration was determined for all three 
fractions which were then separated via SDS-PAGE and analyzed by 
immunoblotting. 
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2.8.3 In vitro modification of protein extracts 
Whole cell protein extract was prepared from 0-6 hour embryos which were 
homogenized, using a dounce homogenizer, in 0.5 ml organelle solubilisation 
buffer per 200 mg dechorionated embryos. After clarification at 13000 x g for 5 
minutes at 4 ºC, the extract was subjected to either, or both, of the treatments 
detailed below. Following in vitro modification, the extracts were separated via 
SDS-PAGE and analyzed via immunoblotting. Note: samples were intentionally 
overloaded in an attempt to discover SNAMA proteins. 
 
2.8.3.1 Acetylation 
Acetylation was performed as described by Simons et al. (1997), which was based 
on Bayer et al. (1996). 
 
2.8.3.2 Phosphorylation and Mg
2+
-precipitation 
Phosphorylation and subsequent Mg
2+
-precipitation were performed as described 
by Blencowe et al. (1995).  
 
2.8.4 Exposure of flies to camptothecin as a means of up-regulating Snama 
Up-regulation of Snama via camptothecin treatment was performed as described 
by Hull & Ntwasa (2010), with modifications. In order to avoid immuno-
reactivity attributable to embryos, only five day old male flies were used in this 
experiment, with a negative control consisting of flies raised on yeast which was 
reconstituted in DMSO lacking camptothecin. One hundred flies from each 
treatment were separately homogenized, using a dounce homogenizer, in 0.5 ml of 
ice-cold, organelle solubilisation buffer. The extracts were clarified by 
centrifugation at 13000 x g for 10 minutes. The supernatant was collected and 
acetylated as described in Section 2.8.3.1. The samples were then subjected to 
SDS-PAGE and immunoblotting analysis. 
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2.9 INVESTIGATION OF POTENTIAL INTERACTION PARTNERS OF 
SNAMA PROTEINS 
 
Anti-SNAMA DCM antibodies were employed in co-immunoprecipitation assays, 
using buffers based on Xu et al. (2009), in order to discover potential interaction 
partners of SNAMA proteins. 
 
Table 2.8: Buffers and solutions used in investigating potential interaction partners of SNAMA 
proteins 
BUFFER/SOLUTION COMPOSITION 
Preparation of protein extracts 
COIP lysis buffer 50 mM Tris-HCl, pH 8.0; 150 mM NaCl;  
1 mM EDTA; 1 % NP-40;  
1 µl/ml protease inhibitor cocktail;  
1 µl/ml DNAse 
COIP wash buffer 50 mM Tris-HCl, pH 8.0; 150 mM NaCl; 
1 mM EDTA; 1 % NP-40 
Extraction of potential interaction partners 
Spot destain solution 500 µl of 30 mM potassium ferricyanide;  
500 µl of 0.1 M sodium thiosulphate  
Spot storage solution 200 mM ammonium bicarbonate 
 
2.9.1 Preparation of protein extracts and co-immunoprecipitation reactions 
Protein samples were prepared from 0-6 hour old dechorionated embryos, mixed 
larval stages, and male-only flies. Samples were homogenized in 1 ml COIP lysis 
buffer, on ice, over a period of 2 hours. Homogenates were clarified via multiple 
rounds of 5 minute long centrifugation at 18000 x g and transferred to a new tube 
between each spin. The protein concentration was determined for all three 
samples after which eppendorf tubes, containing one milligram of embryo, larvae, 
or adult protein extract, were set up in duplicate. Fifteen micrograms of anti-
SNAMA DCM antibody was added to one set of samples, while 15 µg of 
preadsorbed pre-immune serum was added to the other set, for use as a negative 
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control. A positive control reaction was also set up, consisting of 100 µg Positive 
control protein and 15 µg anti-SNAMA DCM antibody. Each of the seven 
reactions’ volumes were made up to 1 ml with COIP lysis buffer and subjected to 
end-over-end mixing overnight at 4 ºC.  
 
2.9.2 Preparation of columns for binding immune-reactive complexes 
Due to the minute volumes used, seven home-made chromatography columns 
were prepared by placing a custom-fitted frit at the bottom of a 1 ml syringe. Each 
column was packed with 20 µl of Chicken IgY Precipitating Resin, equilibrated in 
COIP wash buffer, after which the spouts were sealed and the seven individual 
assays each added to a separate column. The columns were sealed at the top with 
a plunger and subjected to end-over-end mixing at 4 ºC for 4 hours. 
 
2.9.3 Purification and analysis of immune-reactive complexes 
The columns were drained of extract and the resins washed with four column 
volumes of COIP wash buffer, followed by a further two washes lacking 
detergent. Residual liquid within the resins was removed with blotting paper and 
the spouts were again sealed. The resins were resuspended in 30 µl 1X SDS-
PAGE sample buffer, via vortexing, over a period of 30 minutes during which 
time the columns were also placed in a heating block set at 60 ºC. The SDS-
PAGE sample buffer elution was extracted from the columns and analyzed via 
SDS-PAGE.  
 
2.9.4 Extraction of potential interaction partners from gels and identification 
via LC-MS/MS 
After analysis via scanning densitometry, bands of interest were punched out of 
gels using individual, cut pipette tips. Coomassie-stained samples were stored in 5 
% acetic acid whereas silver-stained samples were first destained according to 
Gharahdaghi et al. (1999), before storing in spot destain solution. Samples were 
further processed and identified by LC-MS/MS by the Molecular and Biomedical 
Technology Platform, at the Council for Scientific and Industrial Research, 
Pretoria, South Africa.  
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2.10 BIOINFORMATICS 
 
All nucleotide and peptide sequences, related to Drosophila melanogaster, were 
obtained from FlyBase (St. Pierre et al., 2014). Non Fly-related sequences were 
obtained from Ensembl (Flicek et al., 2014). Sequence alignments were 
performed using DNAMAN (Lynnon BioSoft, version 4.03). Mass spectrometry 
data analysis was performed using ProteinPilot™ software (AB SCIEX, version 
4.0.8085). Protein accession numbers for all samples identified via mass 
spectrometry were acquired from UniProt (The UniProt Consortium, 2014).   
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CHAPTER THREE 
 
3. RESULTS 
 
The single-copy RBBP6 gene is thought to have evolved shortly after the 
emergence of the eukaryotic cell (Pugh et al., 2006). Generally, more 
evolutionarily ancient species produce only one RBBP6 protein from this gene, 
whereas later evolved species produce multiple proteins through alternative 
splicing. Two RBBP6 proteins are predicted to exist in Drosophila melanogaster: 
the 139 kDa SNAMA-PA and 55.6 kDa SNAMA-PB, although neither protein 
has thus far been proven experimentally. This study aims to investigate and 
characterize RBBP6 proteins in Drosophila melanogaster. The SNAMA DCM 
sequence, which is common to both putative SNAMA proteins, was previously 
cloned by Antunes (2008). In the present study, the SNAMA DCM protein was 
heterologously expressed in E. coli, with the intention of performing pulldown 
assays as a means of investigating potential interaction partners of SNAMA 
proteins. Polyclonal antibodies were also raised against the SNAMA DCM 
protein and purified. The antibodies were employed in immunoblots; firstly, to 
discover RBBP6 proteins and secondly, to investigate their spatio-temporal 
regulation. Lastly, the antibodies were used in co-immunoprecipitation assays as 
an alternate approach in investigating potential interaction partners of SNAMA 
proteins. Taken together, this study aims to further our understanding of SNAMA, 
which may in turn provide new insight into mammalian RBBP6 functionality. 
 
3.1 PURIFICATION OF HETEROLOGOUSLY EXPRESSED PROTEINS 
 
Heterologous protein expression was performed using E. coli BL21 (DE3) pLysS 
cells as the host and pET-41a(+) (Figure B1) as the expression vector. Upon 
IPTG-mediated induction of protein expression, the vector is transcribed from a 
start site, located at position 1166 b.p., until the terminator site located at positions 
72-26 b.p. The resultant transcript is translated from an AUG corresponding to the 
ATG located at positions 1095-1093 b.p. on the vector. Translation is terminated 
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at a stop codon corresponding to positions 141-139 of the vector sequence. The 
resultant 35.675 kDa protein contains an N-terminal 25.65 kDa Schistosoma 
japonicum GST solubility and purification tag, followed by a hexa-histidine 
purification tag and both thrombin and enterokinase protein cleavage sites (Figure 
B2). At the nucleotide level, the sequence encoding the 35.675 kDa protein also 
contains an S-tag for sequencing analysis and a C-terminal multiple cloning site 
(MCS) for insertion of desired sequences.  
 
The two bacterial clones utilized in this project were created by Antunes (2008). 
The first clone contains an unmodified pET-41a(+) vector and is referred to in this 
study as the “control” clone. Subsequently, induced protein expression of the 
control clone yields the 35.675 kDa protein described above, and is referred to in 
this study as the 36 kDa control protein (Figure C1). As the control protein 
contains a GST tag, glutathione affinity chromatography was used to purify the 
protein from the bacterial protein extract. Processing of the supernatant fraction 
led to the recovery of a single band, approximately 36 kDa in size, in the elution 
fraction (Figure 3.1) and is consistent with the calculated size of 35.675 kDa 
reported in Figure C1.  
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Figure 3.1: Glutathione affinity chromatography purification of the control protein. The 36 kDa 
control protein, as indicated by red arrows, is present in the supernatant fraction of induced control 
bacterial extract (lane 2) and recovered as a pure protein in the elution fraction (lane 5).  
 
The second bacterial clone features a recombinant pET-41a(+) vector into which 
the SNAMA DCM sequence has been inserted between the BamHI and HindIII 
restriction sites. This second clone, producing a 63 kDa protein (Figure D1), is 
referred to in this study as the SNAMA DCM clone / protein, respectively. The 
control protein and the SNAMA DCM protein are therefore identical in both 
sequence and features, from the amino-terminus up to the BamHI restriction site; 
the sequences differ beyond this point, as the approximately 1.7 kDa sequence 
located between the BamHI and HindIII sites has been replaced by the 29.2 kDa 
SNAMA DCM sequence. Furthermore, insertion of the SNAMA DCM sequence 
causes a frameshift, resulting in the region downstream of the HindIII site to 
change. As such, the SNAMA DCM protein codes for the sequence of pET-
41b(+), as shown in Figure B1, which contains a C-terminus octa-HIS tag instead 
of the octa-proline tract found in the control protein.  
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In contrast to the control protein, and consistent with the results of Antunes 
(2008), the SNAMA DCM protein was recovered as an inclusion body following 
protein expression and extraction. Glutathione affinity chromatography could not 
be utilized in order to purify the SNAMA DCM protein, as the protein was not 
correctly folded and could therefore not interact with the GST binding site of the 
glutathione resin. As such, the SNAMA DCM protein had to be purified via its 
two HIS tags. The inclusion body pellet was first solubilized in a urea-based 
buffer and thereafter subjected to immobilized metal-ion affinity chromatography 
(IMAC) (Figure 3.2). The elution fraction contained predominantly SNAMA 
DCM protein but also contaminating bacterial proteins. Once correctly refolded, 
the SNAMA DCM protein can be purified from the contaminating proteins via 
glutathione affinity chromatography.  
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Figure 3.2: IMAC purification of SNAMA DCM protein. Co-purifying, positively-charged 
bacterial proteins contaminate the elution fraction, which predominantly contains SNAMA DCM 
protein. 
 
3.2 DENATURED SNAMA DCM PROTEIN WAS UNABLE TO REFOLD 
VIA DIALYSIS 
 
In order to perform pulldown assays, the SNAMA DCM protein must exist in its 
correct tertiary structure. The assay is thus dependant on the correct morphology 
of two components of the SNAMA DCM protein. Firstly, the N-terminal GST tag 
of the SNAMA DCM protein must be correctly folded, in order to anchor the 
protein to glutathione-agarose. Secondly, the SNAMA DCM component must 
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also be correctly refolded in order for it to be representative of native sites of 
wild-type SNAMA proteins, so as to allow credible interaction partners to bind.  
 
IMAC-purified SNAMA DCM protein was refolded according to the two 
methodologies of Antunes (2008) which were shown to yield enzymatically-
active SNAMA DCM protein. The two approaches differ only in the ex/inclusion 
of additives in the dialysis buffer, although the absence of additives severely 
reduces refolding efficiency (Antunes, 2008). In accordance with Antunes (2008), 
glutathione affinity chromatography (Figure 3.3) was used to evaluate whether the 
SNAMA DCM protein was correctly refolded following dialysis. The results of 
this study are not consistent with those of Antunes (2008). In both refolding 
strategies, SNAMA DCM protein was not recovered in the elution fractions; 
instead, it was present in the unbound and wash fractions. This indicates that the 
GST tag of the SNAMA DCM protein was unable to interact with the glutathione 
resin, as the tag was not refolded into its correct tertiary structure. This is 
supported by the fact that the same columns, used for recovering refolded 
SNAMA DCM protein, were able to purify control protein. Low efficiency of 
refolding was ruled out after failing to recover any refolded SNAMA DCM 
protein, after processing a twenty-fold excess compared to the amount processed 
by Antunes (2008).  
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Figure 3.3: Recovery of refolded SNAMA DCM protein via glutathione affinity chromatography. 
Denatured SNAMA DCM protein was dialyzed according to the two methodologies of Antunes 
(2008) reported to yield enzymatically active SNAMA DCM protein: A) with additives, B) 
without additives. In both strategies, SNAMA DCM protein is absent from the elution fraction and 
instead recovered in the flow-through and wash fractions, thereby indicating that the SNAMA 
DCM protein had not been correctly refolded. 
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In order to correct for misfolded SNAMA DCM protein, the refolding strategies 
of Antunes (2008) were modified. Refolding in the absence of additives was 
abolished due to the formation of precipitated SNAMA DCM protein (Figure 
3.3B, lane 3), which did not occur when employing additives. Further 
modifications were made based on features of the SNAMA DCM protein. As the 
active site of the SNAMA DCM protein was expected to co-ordinate two zinc 
ions (Mather, 2005), EDTA was omitted from the refolding buffer which instead 
was supplemented with zinc chloride. Furthermore, seven cysteine residues are 
involved in disulfide bond formation in the active site (Mather, 2005), hence a 
redox system was introduced into the refolding buffer. Instead of dialyzing against 
a single buffer change, multiple buffer changes were utilized, including, in some 
attempts, a crude, continuous flow system. However, these modifications were 
ineffective in correcting for misfolded SNAMA DCM protein (Figure 3.4) and the 
procedure was abandoned. Instead, potential interaction partners of SNAMA 
proteins were investigated through co-immunoprecipitation assays (Section 3.5). 
 
 
Figure 3.4: Glutathione affinity chromatography of SNAMA DCM protein following dialysis 
with redox-buffer. The refolding strategy of Antunes (2008) was modified in an attempt to correct 
for misfolded SNAMA DCM protein. Likewise, the modifications did not yield correctly refolded 
SNAMA DCM protein. 
48 
 
3.3 EVALUATION OF THE SPECIFICITY OF THE ANTI-SNAMA DCM 
ANTIBODIES 
 
The author was provided with unpurified pre-and-post immune sera. In order to 
assess whether antibody proliferation was successful, two identical immunoblots, 
containing IMAC-purified SNAMA DCM protein, were probed with either 
unpurified serum. SNAMA DCM protein was detected exclusively by the post-
immune serum (results not shown). This indicated that the pre-immune serum did 
not contain any antibodies which inherently cross-react with SNAMA DCM 
protein and further demonstrated that antibody production against SNAMA DCM 
protein had occurred post-administration of the immunogen. Antibodies had also 
been elicited against the co-purified, positively-charged bacterial proteins which 
contaminated the immunogen (Figure 3.5, lane 1). Furthermore, antibodies would 
also have been produced against antigenic sites arising from the tag components, 
i.e. amino acids 1-285 fused N-terminally and amino acids 546-559 fused C-
terminally to the SNAMA DCM component protein.  
 
The procedure for separating anti-SNAMA DCM antibodies from the post-
immune serum was initiated by preparing protein extracts from both induced 
bacterial clones (Figure 3.6). As the samples were cross-linked via reductive 
amidation to aldehyde-agarose, the samples were prepared using buffers which 
lacked amine-containing compounds - thus accounting for the change in 
methodology compared to Section 3.1, for protein extraction and purification. The 
post-immune serum was applied to the column containing cross-linked positive 
control protein extract (Figure 3.6, lane 6), with the effect that only antibodies 
specific for the SNAMA DCM protein and bacterial proteins present in the 
immunogen, were pulled out. These selected antibodies were thereafter pre-
adsorbed on the second column containing cross-linked negative control protein 
extract (Figure 3.6, lane 3), in which antibodies specific for the bacterial proteins 
as well as the N-terminal tag of the SNAMA DCM component protein were 
sequestered. This purification procedure yielded antibodies specific for the 
SNAMA DCM component, with the only contaminating antibodies being those 
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specific for the C-terminal tag of the SNAMA DCM protein. Given that the C-
terminal tag is 5 % of the length of the SNAMA DCM, the contaminating 
antibodies are considered negligible. Thus, this resultant antibody sample 
represents the end-point of the purification procedure and is referred to as “anti-
SNAMA DCM antibodies”. Furthermore, the pre-immune serum was also pre-
adsorbed on the negative control extract column to allow for its use as a negative 
control in various applications. 
 
 
Figure 3.5: Immunoblot of developmental stages of D. melanogaster probed with unpurified post-
immune serum. The SNAMA DCM protein is detected in lane 1 along with co-purified, positively-
charged bacterial proteins. As a result, the immune-reactive bands in D. melanogaster samples 
may be attributable to cross-reactivity. Hence, the post-immune serum required purification in 
order to select for only anti-SNAMA DCM antibodies. E = embryo, L = larvae, P = pupae. 
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Figure 3.6: Protein extracts utilized in purifying anti-SNAMA DCM antibodies from post-
immune serum. A protein extract from the uninduced control bacterial cells (lane 2) will yield an 
identical protein complement to uninduced SNAMA DCM protein extract. Upon IPTG induction 
of protein expression, the induced control (lane 3) and SNAMA DCM (lane 5) bacterial protein 
extracts differ only in the production of one protein: the 36 kDa control protein (lane 4) and 63 
kDa SNAMA DCM protein, respectively. The first 285 amino acids of the control protein are 
identical to the N-terminal tag of the SNAMA DCM protein (refer to Figures C1 and D1). Thus, 
the control bacterial protein extract is representative of every possible antigenic site that may arise 
from the SNAMA DCM bacterial protein extract, with the exception of the SNAMA DCM 
component (amino acids 286-545) and C-terminal tag (amino acids 546-559) of the SNAMA 
DCM protein. This represents a strategy for purifying for only anti-SNAMA DCM antibodies.  
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3.4 SPATIO-TEMPORAL EXPRESSION OF SNAMA PROTEINS 
 
3.4.1 Temporal expression of SNAMA proteins 
In order to verify the existence of the two putative SNAMA proteins, as well as 
determine the temporal expression of any other unknown SNAMA proteins, 
protein extracts were prepared from the major morphological stages of D. 
melanogaster development, namely: embryo, larvae, pupae and adult. These 
extracts were analyzed via immunoblotting, utilizing anti-SNAMA DCM 
antibodies which had been effectively purified of all contaminating antibodies 
(Figure 3.7). The results of this experiment were mostly identical to those 
presented in Figure 3.5, which was probed with unpurified post-immune serum. In 
both Figures 3.5 and 3.7, SNAMA-PA was not detected, while the existence of 
SNAMA-PB – if present – is indeterminable from the immune-reactive bands 
which span from ~ 17 kDa to ~ 55 kDa. These immune-reactive proteins are most 
abundant during early stages of development and diminish with age, being 
completely absent in adult male flies (Figure 3.7) and virgin females (results not 
shown). The presence of immune-reactive proteins in the combined male and 
female fly extract (Figure 3.5, lane 9), is therefore attributable to the embryos of 
fertilised female flies. These immune-reactive proteins are therefore maternally 
deposited, which is in agreement with the observation that these immune-reactive 
proteins are most abundant during early stages of development.  
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Figure 3.7: Immunoblot of developmental stages of D. melanogaster probed with anti-SNAMA 
DCM antibodies. Bacterial proteins were not detected thereby demonstrating the effectiveness of 
the antibody purification strategy as well as the specificity of the anti-SNAMA DCM antibodies. 
The results of this experiment are consistent with those of Figure 3.5: SNAMA-PA is not detected 
whilst the presence of SNAMA-PB is indeterminable. Furthermore, the immune-reactive proteins 
which span from ~ 17 kDa to ~ 55 kDa are most abundant during early stages of development and 
diminish with age. 
 
 
3.4.2 Spatial localization of SNAMA proteins 
The temporal expression studies described in Section 3.4.1 did not reveal either 
putative SNAMA protein, although the anti-SNAMA DCM antibodies did detect 
multiple immune-reactive proteins in early stages of D. melanogaster 
development. In order to further analyze these proteins, 0-6 hour old embryos 
were fractionated into nuclear, post-nuclear and remaining cytosolic fractions, via 
differential centrifugation. Two identical immunoblots, containing these protein 
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fractions, were probed with either pre-adsorbed pre-immune serum or anti-
SNAMA DCM antibodies (Figure 3.8). This experiment verifies an earlier 
statement that the pre-immune serum does not detect the SNAMA DCM protein. 
However, the results demonstrate inherent cross-reactivity of the chicken 
antibodies for various D. melanogaster proteins, due to the detection of common 
bands by both pre-adsorbed pre-immune serum and anti-SNAMA DCM 
antibodies. Immune-reactive proteins range from ~ 17 kDa to ~ 55 kDa – 
consistent with previous results (Figures 3.5 and 3.7). Six unique bands (yellow 
arrows) are detected exclusively by the anti-SNAMA DCM antibodies. These 
bands all localize to the post-nuclear fraction and are of the following 
approximate sizes: 20, 28, 33, 35, 37 and 55 kDa. It is tempting to speculate that 
the ~55 kDa band may be putative 55.6 kDa SNAMA-PB. 
 
 
Figure 3.8: Immunoblot of subcellular fractionated, 0 – 6 hour old D. melanogaster embryos. Two 
identical blots were probed with either (A) pre-adsorbed pre-immune serum, or (B) anti-SNAMA 
DCM antibodies. Detection of identical bands in both blots indicates antibody cross-reactivity. 
Consequently, any band detected in blot A would negate its corresponding band in blot B. Six 
unique bands are detected in blot B - as indicated by the yellow arrows - and are all present in the 
post-nuclear fraction. 
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3.4.3 In vitro acetylation of protein extracts did not result in the detection of 
SNAMA-PA 
The M. musculus RBBP6 protein, PACT, could only be detected via 
immunoblotting after it was first acetylated in vitro (Simons et al., 1997). 
Acetylation neutralizes the positive charge contributed by the lysine-rich tracts, 
which are thought to interfere with the movement of RBBP6 proteins into the 
separating layer of an SDS-PAGE gel. Furthermore, PACT was also shown to co-
precipitate along with SR proteins, when using a selective in vitro precipitation 
method specific for RS-domain-containing proteins (Simons et al., 1997). The 
basis for this selective precipitation technique is phosphorylation of serine-rich 
tracts constituting the RS-domain, with Mg
2+
 then forming intra-and-inter ionic 
cross-links between phosphoserines, with resultant precipitation. Both these 
procedures were performed on protein extracts from 0-6 hour old embryos, which 
were thereafter analyzed via immunoblotting (Figure 3.9) as a means of detecting, 
specifically, SNAMA-PA. Cross-reactivity of the anti-SNAMA DCM antibodies 
for SR proteins is confirmed in both lanes 4 and 6 of Figure 3.9, owing to the 
detection of SR proteins in the pellet fraction of sample treated with this selective 
precipitation technique. A similar range of immune-reactive bands is observed in 
all lanes containing embryo protein extract, regardless of whether the samples 
were subjected to acetylation, selective precipitation, or both procedures. 
Immune-reactive proteins are most discernible in lane 6 of Figure 3.9, which 
clearly shows seven distinct bands ranging from approximately 25 kDa to 45 kDa. 
These bands mostly appear consistent with the bands detected in previous results 
(see, for example, Figure 3.5, lane 2). Despite severely overloading protein 
extracts, SNAMA-PA was not detected. SNAMA-PB would not be expected as it 
lacks the majority of the C-terminal RS-domain present in SNAMA-PA. 
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TREATMENT ORDER IN WHICH PROCEDURES WERE PERFORMED 
Extraction in 
organelle 
solubilisation buffer 
N/A N/A N/A 1 1 1, 3* 1 1 
Phosphorylation & 
Mg
2+
-precipitation 
N/A N/A N/A 2 2 2 - - 
Acetylation N/A N/A N/A - - 4 - 2 
LANE 1 2 3 4 5 6 7 8 
 
Figure 3.9: Immunoblot of acetylated protein extracts from 0-6 hour old D. melanogaster 
embryos. Samples were subjected to acetylation and/or a selective precipitation procedure, in order 
to detect SNAMA-PA - specifically. These procedures, however, did not result in the detection of 
SNAMA-PA.* The SR-precipitated pellet fraction was resusupended in HEPES buffer, prior to 
acetylation. P = pellet fraction; S = supernatant fraction.  
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3.4.4 Up-regulation of Snama-RA in male flies did not result in the detection 
of SNAMA proteins 
Hull and Ntwasa (2010) demonstrated an inverse relationship between Dmp53 and 
Snama mRNA expression levels. After subjecting flies to camptothecin-laced 
food for 48 hours, their results showed that Dmp53 mRNA is up-regulated in 
response to DNA damage. However, following a subsequent recovery period of 
24 hours, Snama mRNA is up-regulated while Dmp53 mRNA is down-regulated 
(Hull and Ntwasa, 2010). Thus, in this experiment, protein extracts were prepared 
from flies 24 hours after camptothecin exposure, as yet another approach towards 
discovering SNAMA proteins. In order to exclude bands attributable to antibody 
cross-reactivity, as seen in embryo extracts, male-only protein extracts were 
prepared and thereafter acetylated, prior to analysis via SDS-PAGE and 
immunoblotting (Figure 3.10). Acetylated SNAMA DCM protein (Figure 3.10, 
lane 4) is slightly larger than non-acetylated SNAMA DCM protein (Figure 3.10, 
lane 3) due to the covalent attachment of acetyl groups, thus demonstrating the 
viability of the acetylation methodology. While false-positives have been 
effectively avoided, no immune-reactive proteins were detected. The absence of 
either putative SNAMA protein, as well as any other immune-reactive protein, in 
protein extracts prepared from male flies, is therefore consistent with previous 
results (Figure 3.7, lane 6). Failure to detect either SNAMA protein in this 
experiment could possibly suggest that camptothecin treatment was ineffective in 
up-regulating SNAMA proteins.  
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MANIPULATION DURATION (HOURS) 
Camptothecin in 
DMSO 
N/A N/A N/A N/A - 72 48 - - 
DMSO only N/A N/A N/A N/A - - - 72 48 
Recovery N/A N/A N/A N/A - - 24 - 24 
Acetylated - - - + + + + + + 
LANE 1 2 3 4 5 6 7 8 9 
 
Figure 3.10: Immunoblot of protein extracts prepared from male flies exposed to camptothecin. 
Flies were fed camptothecin in order to indirectly up-regulate Snama mRNA, and potentially, 
subsequent SNAMA proteins. This measure also did not result in the detection of either putative 
SNAMA protein. 
 
3.5 CO-IMMUNOPRECIPITATION ASSAYS AND LC-MS/MS 
IDENTIFICATION OF IMMUNE-COMPLEX PROTEINS 
 
The inability to refold SNAMA DCM protein as described in Section 3.2 ruled out 
the option of performing pull-down assays. Instead, co-immunoprecipitation 
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assays were performed as a means of investigating potential interaction partners 
of SNAMA proteins. Protein extracts were prepared from various developmental 
stages and incubated in separate reactions with either anti-SNAMA DCM 
antibodies or, for the purpose of identifying false-positives, pre-adsorbed pre-
immune serum. Captured immune-complexes were analyzed via SDS-PAGE 
(Figure 3.11). The 68 kDa band common to lanes 2-9 in Figure 3.11 represents the 
heavy chain of the chicken antibodies utilized in each assay. Recovery of 
SNAMA DCM protein in a positive control reaction (Figure 3.11, lane 9) 
demonstrates the viability of the methodology. The embryo sample (Figure 3.11, 
lane 3) was the only stage of development in which unique bands were observed. 
This result was consistent among biological replicates (Figure 3.11c). In 
agreement with the findings of Figure 3.8, a unique band was detected in Figure 
3.11c at 55 kDa while no band was detected at 139 kDa – the anticipated sizes of 
the two putative SNAMA proteins.  
 
Unique bands were manually excised from gels and sent for identification via 
mass spectrometry (Section 2.9.4). Negative control bands were also excised and 
identified in cases where uncertainty existed regarding corresponding control and 
test bands – e.g. two bands in lane 3 and a single band in lane 2 of Figure 3.11a 
are all approximately 40 kDa in size. This approach allowed for the exclusion of 
several false-positives (data not shown); the identities of the remaining unique 
proteins, across replicate experiments, are reported in Table 3.1.  
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Figure 3.11: SDS-PAGE analysis of immune-complex proteins isolated from co-
immunoprecipitation assays. (A) Samples were prepared from 0-6 hour embryos (lanes 2 & 3), 
combined larval stages (lanes 4 & 5), and male-only flies (lanes 6 & 7). For each stage of 
development, a negative control assay was performed (lanes 2, 4, 6). Equivalent bands between 
both test and control lanes, for a given stage of development, are negated. Unique bands were 
detected exclusively in the embryo sample (lane 3). (B & C) Bands identified by LC-MS/MS.  B) 
Lanes 2 and 3 from the gel in (A), whereas C) is a replicate gel stained with silver-stain.  The 
proteins identified in these two gels are presented in Table 3.1.  
 
 
 
 
 
60 
 
Table 3.1: Identities of unique proteins isolated from co-immunoprecipitation assays 
SAMPLE
1
 UNIPROT 
ACCESSION  
CODE 
PROTEIN NAME
2
 Mr 
(kDa) 
PROTSCORE
3
 
TRANSCRIPTION AND TRANSCRIPTIONAL REPRESSION 
SS22a Q94883_DROME DNA REPLICATION-
RELATED ELEMENT 
FACTOR (DREF) 
80.727 1.24 
SS95a HP1_DROME HETEROCHROMATIN 
PROTEIN 1 
23.185 1.31 
SS18a & 
SS21 & 
SS22b 
Q24156_DROME STONEWALL 112.913 0.87 
0.94 
1.08 
mRNA PROCESSING 
SS18b & 
CBB33 
Q9W2K4_DROME CG4266-PA 130.427 1.74 
0.89 
SS18c & 
SS26b 
Q9W1K4_DROME EGALITARIAN 112.129 1.43 
1.15 
SS95c Q8SYG4_DROME PHOSPHORYLATED 
ADAPTER FOR RNA 
EXPORT (PHAX) 
53.965 1.17 
PROTEIN SYNTHESIS AND FOLDING 
CBB55a Q9TWZ1_DROME D-ERp60 / PROTEIN 
DISULFIDE ISOMERASE 
(PDI) 
55.373 2.26 
SS29 EF1A2_DROME ELONGATION FACTOR 1-
ALPHA 2 
50.663 2.5 
CBB43a EF1G_DROME ELONGATION FACTOR 1-
GAMMA 
48.968 6 
CBB90a EF2_DROME ELONGATION FACTOR 2 94.459 27.74 
SS26a Q4V5H1_DROME PEPTIDYL-PROLYL CIS-
TRANS ISOMERASE 
20.182 1.62 
CBB43b RL4_DROME 60S RIBOSOMAL PROTEIN 
L4 
45.026 2.37 
CBB35 Q9UAN1_DROME 60S RIBOSOMAL PROTEIN 
L22 
30.611 2 
METABOLISM 
CBB90b PYG_DROME GLYCOGEN 
PHOSPHORYLASE 
96.997 2 
CBB55b KPYK_DROME PYRUVATE KINASE 57.44 2.75 
OTHER 
SS38 Q9VSY1_DROME CG4022-PA 57.294 2 
SS22c Q9VQ83_DROME CG10874-PA 35.041 1.57 
SS95b Q6IGH5_DROME HDC06258 17.442 0.78 
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CBB28a ADT_DROME ADP, ATP CARRIER 
PROTEIN 
34.215 5.64 
CBB28b HSP27_DROME HEAT SHOCK PROTEIN 27 23.617 4 
SS33 Q9VXL1_DROME MIND-MELD, isoform C 150.547 0.87 
SS22d Q4ABH1_DROME MUSCLE-SPECIFIC 
PROTEIN 300, isoform D 
1405.148 0.97 
SS95d Q9VKQ3_DROME RIBOSOME BIOGENESIS 
PROTEIN WDR12 
HOMOLOG 
47.222 1.47 
SS95e Q9W003_DROME SPINOPHILIN 233.209 1.86 
CBB90c TERA_DROME TRANSITIONAL 
ENDOPLASMIC 
RETICULUM ATPASE 
TER94 
88.859 9.72 
CBB55c TBB1_DROME TUBULIN BETA-1 CHAIN 50.147 16.55 
CBB43c VIT2_DROME VITELLOGENIN-2 49.66 14.35 
CBB28c VDAC_DROME VOLTAGE-DEPENDENT 
ANION-SELECTIVE 
CHANNEL 
30.55 8.13 
1 Samples beginning with “CBB” represent bands extracted from the gel depicted in Figure 3.11b, 
whereas samples beginning with “SS” were isolated from the gel shown in Figure 3.11c. The 
number associated with each sample, represents the approximate mass (kDa) of the protein when 
extracted from a gel. The lower-case alphabetical letter differentiates between multiple proteins 
identified from a single band. 2 Proteins are listed alphabetically within broadly-defined groups, 
based on their biological activity reported at UniProt. 3 ProtScore is a relative score for 
determining and comparing the overall coverage of a protein. The score is based on the cumulative 
confidence scores of all peptide fragments detected for an individual protein. A score of ≥ 2 
represents ≥ 99 % confidence, while a score of ≥ 1 is representative of ≥ 90 % confidence. Further 
details about ProtScore, including formulae and further ProtScore confidence approximations, can 
be found in the ProteinPilot™ software Help file. 
 
 
 
 
 
 
 
62 
 
CHAPTER FOUR 
 
4. DISCUSSION 
 
In this study, immunological and biochemical approaches were undertaken in 
order to characterize SNAMA proteins. The spatio-temporal regulation of 
SNAMA proteins was investigated through immunoblotting, while potential 
interaction partners were investigated through co-immunoprecipitation assays. 
These studies were performed with a view towards elucidating the roles of 
SNAMA and thereby also possibly those of RBBP6 proteins in general. 
 
4.1 THE PURIFIED ANTI-SNAMA DCM ANTIBODIES DID NOT 
DETECT SNAMA-PA BUT LIKELY DETECTED SNAMA-PB 
 
This study sought to identify and characterize RBBP6 proteins in D. 
melanogaster. As the two putative SNAMA proteins share the same N-terminal 
493 residues, polyclonal chicken antibodies were produced against a recombinant 
protein comprising the first 260 residues - which includes the three structured 
domains referred to as the DCM (Figure 1.4). Anti-SNAMA DCM antibodies 
were successfully purified from the post-immune serum and were shown to be 
specific for the positive control protein (Figure 3.7). Further validation of 
antibody specificity is provided by the mass spectrometry result in Figure E1, 
which verifies the identity of the 63 kDa positive control protein as recombinant 
SNAMA DCM protein.  
 
Utilization of the anti-SNAMA DCM antibodies in immunoblots did not result in 
the detection of a 139 kDa band approximating SNAMA-PA. This is not 
surprising, given the problems encountered by other researchers working on 
RBBP6 proteins. Jones et al. (2006) reported raising antibodies against SNAMA 
in rabbit, although they also failed to detect SNAMA-PA. At the time, the 
existence of SNAMA-PB was not known, thus no mention was made regarding 
detection of SNAMA-PB with these rabbit antibodies.  
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In addition, detection of M. musculus RBBP6 protein has been demonstrated 
(Simons et al., 1997), although this was only possible after the sample was first 
chemically modified through acetylation, in order for it to be visualized on a SDS-
PAGE gel. Likewise, in the present study, acetylation was therefore also 
performed. This procedure would effectively neutralize the positively-charged 
lysine residues found primarily at the C-terminus of SNAMA-PA in the form of 
two lysine-rich tracts (Table 1.1), which was suspected by Simons et al., (1997) to 
be responsible for the difficulties in visualizing M. musculus RBBP6. The 
acetylation procedure also modifies all primary amine-containing residues and 
hydroxyl-containing residues such as serine, threonine and tyrosine (Abello et al., 
2007), which would drastically decrease the pI of SNAMA-PA. Although this 
procedure was demonstrated to have worked correctly due to the acetylated 
positive control protein having a slightly larger size than the non-acetylated 
positive control (Figure 3.9, lanes 3 & 4), SNAMA-PA was still undetectable. 
Furthermore, the results of this study appear to echo the results of a study on H. 
sapiens RBBP6, in which anti-DWNN antibodies could not detect native RBBP6 
proteins in extracts from HEK293 cells (Chibi et al., 2008).  
 
As the difficulties experienced in detecting RBBP6 proteins are not confined to 
one organism or research group, it is likely that the domains and subsequent 
properties of RBBP6 proteins may interfere with the ability to detect these 
proteins. For instance, the RING domain present in RBBP6 proteins is known to 
be highly susceptible to aggregation (Borden, 2000), as is the RS-domain. Thus, 
considering the positive control protein lacks the RS-domain and the associated 
physicochemical implications such as increased susceptibility to aggregation and 
an extremely high isoelectric point, this could account for why it could be 
detected but not native SNAMA proteins.  
 
In the event that SNAMA-PA could not be detected due to low expression levels, 
two techniques were performed as a means of facilitating SNAMA-PA detection. 
Indirect up-regulation of Snama-RA through camptothecin treatment has been 
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demonstrated by Hull & Ntwasa (2010), although it does not necessarily mean 
that SNAMA-PA would, in turn, be up-regulated. Regardless, this approach did 
not result in the detection of SNAMA-PA (Figure 3.10). As the second 
biochemical approach employed in this study, protein extracts were subjected to 
phosphorylation followed by Mg
2+
 precipitation. This technique has been shown 
to select for RS-domain-containing proteins (Blencowe, 1995), which therefore 
includes SNAMA-PA. However, this approach did not result in the detection of 
SNAMA-PA either.  
 
SNAMA-PB lacks the majority of the RS-domain, thus its isoelectric point is far 
lower than that of SNAMA-PA (Table 1.1). A band of approximately 55 kDa is 
detected in Figures 3.8 and 3.11, which may be SNAMA-PB. Thus, this 55 kDa 
band is detected via both immunoblotting and co-immunoprecipitation assays, 
which is suggestive of a direct interaction with the antibody. In support of this, the 
55 kDa band was not detected in the pellet fraction of Figure 3.9, which selected 
for RS-domain-containing proteins. Unfortunately, however, SNAMA-PB was not 
one of the proteins identified from the 55 kDa band sequenced via mass 
spectrometry (Table 3.1), although this does not discount the possibility of 
SNAMA-PB being identified in future, possibly even through a replicate 
experiment. This protein localizes to the post-nuclear fraction (Figure 3.8, lane 4), 
as do all unique bands identified in Figure 3.8. While this would be unusual for 
SNAMA-PA, due to the multiple bipartite NLS as well as nucleus-targeting 
sequences within the RS-domain, as SNAMA-PB lacks these regions, it seems 
reasonable that it could localise to other organelles, typically found in the post-
nuclear fraction. Examples include mitochondria, ribosomes and Golgi apparati – 
the localization of SNAMA-PB to the ribosomes or Golgi apparati is consistent 
with a role in protein folding and quality control, as suggested by Kappo et al. 
(2012) for RBBP6 proteins. This banding pattern could be reminiscent of 
DWNNylation, although it would have shown in the mass spectrometry results 
(Table 3.1) as a DWNN domain present on all of the proteins. Thus, the MS data 
has demonstrated that these bands are not attributable to DWNNylation. This 
potential SNAMA-PB is expressed at high levels in the early stages of 
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development and is absent in adults (Figures 3.5, 3.8 & 3.11). Furthermore, the 
detection of SNAMA-PB in adult female samples is most likely due to the 
presence of embryos in fertilised female flies. This agrees with Northern blot 
analysis conducted by Mather (2005), which also showed higher levels of 
SNAMA transcripts in the early stages of development. Moreover, this is also in 
agreement with the high-throughput data of Daines et al. (2011) (Table 4.1), 
which shows that Snama is most actively transcribed during the early stages of 
development, and decreases thereafter. Snama is thereafter only up-regulated in 
female flies.  
 
Table 4.1: Relative transcription levels for Snama throughout the Drosophila melanogaster life-
cycle 
STAGE EMBRYO 
2-4 hours 
EMBRYO 
14-16 
hours 
LARVAE 
(average 
of 3 
instar 
stages) 
PUPAE 
(stage 1) 
PUPAE 
(stage 2) 
FLY 
(male)  
72 
hours 
FLY 
(female) 
72 hours 
RPKM 31 9 4 6 5 8 25 
The data in this table is derived from the results of Daines et al. (2011). RPKM: reads per kilobase 
per million reads – refer to Daines et al. (2011) for a detailed explanation of RPKM values. RPKM 
values have been rounded off to the nearest whole number and indicate that Snama is most 
abundantly transcribed during early stages of embryonic development and in female flies.  
 
4.2 ANTI-SNAMA DCM ANTIBODIES ALSO CROSS-REACT WITH RS-
DOMAIN-CONTAINING PROTEINS 
 
The original technique of Mg
2+
 precipitation (Zahler et al., 1992) resulted in the 
detection of a conserved set of proteins, with sizes of 20, 30, 40, 55 and 75 kDa, 
collectively referred to as SR proteins. This Mg
2+
-dependent precipitation 
procedure is thought to occur through Mg
2+
 mediating ionic cross-linking between 
phosphoserines on adjacent RS-domain containing proteins, with resultant protein 
precipitation (Zahler et al., 1992). While modifications to the original procedure 
by others resulted in additional RS-domain-containing proteins being discovered, 
Simons et al. (1997) have demonstrated that the M. musculus RBBP6 protein, 
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PACT, can be selectively purified via this approach. Unfortunately, this technique 
did not result in the detection of SNAMA-PA.  
 
This procedure was demonstrated to have worked correctly, as well as 
demonstrate cross-reactivity of the anti-SNAMA DCM antibodies for RS-domain-
containing proteins, through the immunological detection of Mg
2+
-precipitated 
proteins in the pellet fraction of Figure 3.9. In addition, some of these proteins had 
sizes equivalent to those shown by Blencowe et al. (1995), thus further supporting 
unintended cross-reactivity of anti-SNAMA DCM antibodies for RS-domain-
containing proteins. Furthermore, the identification of one of these immune-
reactive proteins as an SR protein was confirmed by the identification of a 
Drosophila SR protein, CG4266 (Shepard & Hertel, 2009) in Table 3.1. This 
cross-reactivity could be due to an epitope having formed by either the SR or RS 
dipeptide in the SNAMA DCM sequence (Figure 1.4) located at residues 74-75 
and 185-186, respectively, which could resemble a phospho-epitope present on 
CG4266. This would not be unusual as anti-PACT antibodies raised against an 
epitope generated on the RS-domain cross-reacted with other RS-domain-
containing proteins (Simons et al., 1997). 
 
The presence of CG4266 could also be as a result of a genuine interaction 
between either of the two SNAMA proteins and CG4266 - either directly, or 
indirectly through complex association. Like all SR proteins, CG4266 is predicted 
to function in mRNA processing. Despite this being a function common to all SR 
proteins, individual family members do appear to have distinct functions (Zhong, 
2009). Some of these functions include the facilitation of RNA transport (Sapra et 
al., 2009). Indeed the anti-SNAMA DCM antibodies also interacted with 
PHOSPHORYLATED ADAPTER FOR RNA EXPORT (PHAX). Furthermore, 
as is shown in Table 1.2, Scott et al. (2003) demonstrate that the SR-rich splicing 
factor kinase (SRPK1) phosphorylates M. musculus RBBP6. Thus SNAMA 
proteins can be expected to interact with SR proteins, either directly, or as part of 
a protein complex, as both RBBP6 proteins and SR proteins are known to localize 
to nuclear speckles.  
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4.3 SNAMA MAY INTERACT WITH A WIDE RANGE OF PROTEINS – 
MANY OF WHICH FUNCTION IN TRANSCRIPTION AND mRNA 
PROCESSING 
 
Our group has recently attempted to identify potential protein transcription factors 
and regulatory proteins that bind to the promoter of Snama (Mokgohloa, L., 
unpublished). One of the proteins identified was the the transcription regulatory 
factor DREF (DNA replication-related element-binding factor). This transcription 
factor was also identified in this study (Table 3.1). DREF is known to control the 
expression of proteins playing a role in cell proliferation through their function as 
DNA replication, transcription and cell cycle regulators, and has appropriately 
been labelled the “master key for cell proliferation” (Matsukage et al., 2008). 
Interaction between either of the two SNAMA proteins with DREF fits in well 
with the results of Jones et al. (2006), who demonstrate the importance of 
SNAMA in cell-cycle control and cell proliferation. The fact that DREF was 
captured in this study, as well as another study from our group involving a 
completely different approach, strongly suggests a direct interaction between 
DREF and SNAMA.  
 
The proteins listed in Table 3.1 have diverse roles within a cell. A fair number of 
proteins could easily be surmised to accommodate roles played by RBBP6 
proteins. For instance, numerous proteins involved in transcription and mRNA 
processing are present. These are known functions of RBBP6 proteins. 
Furthermore, it could be speculated that the presence of Vitellogenin-2 in Table 
3.1 may also imply that SNAMA proteins are involved in nutrient synthesis, as 
RBPL1 was shown to directly affect Vitellogenin-2 protein levels (Huang et al., 
2013). As the two SNAMA proteins have vastly different isoelectric points as 
well as C-terminal domains, the two SNAMA proteins are likely to localize to 
different cellular locations and perform different cellular roles. For instance, the 
RS-domain of SNAMA-PA may result in it localizing to the nucleus where it 
could perform transcriptional activities or mRNA processing activities, whereas 
SNAMA-PB, which lacks the RS-domain and nuclear localization signals, may 
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remain within the cytosol or on organelle membranes. Table 3.1 contains 
numerous proteins involved in protein folding, such as HSP27 and PDI. 
Considering that proteasomes localize to the outer surface of endoplasmic reticuli 
(Wojcik & DeMartino, 2003) and ER are expected in the post-nuclear fraction of 
Figure 3.8, the 55 kDa band could be SNAMA-PB involved in a protein quality 
control capacity, as suggested by Kappo et al. (2012). No evidence was found for 
DWNNylation, as the mass spectrometry analysis would have identified a DWNN 
domain on at least some of the proteins isolated, which was not the case. Thus 
further investigation is needed to evaluate the credibility of each potential 
interaction partner. 
 
4.4 CONCLUSIONS  
 
 The polyclonal anti-SNAMA DCM antibodies produced in this study are 
specific for the SNAMA DCM protein but also cross-react with other RS-
domain-containing proteins. This cross-reactivity is most likely due to a 
common epitope formed by an RS or SR dipeptide located in the DCM. 
 
 The putative SNAMA-PA protein was not detected in this study, despite 
attempts at up-regulating SNAMA-PA levels and biochemical approaches 
aimed at enriching extracts for SNAMA-PA through selective 
precipitation. It is thought that the protein’s C-terminal structure may 
interfere with the ability to visualize it via SDS-PAGE, which could not be 
overcome through acetylation as is the case for M. musculus RBBP6. 
 
 It is likely that the putative 55.6 kDa SNAMA-PB protein has been 
detected via the immunological approach undertaken in this study. The 
spatio-temporal regulation of an immune-reactive 55 kDa protein is 
consistent with what is expected for SNAMA-PB as are the physico-
chemical properties of this protein as determined by biochemical 
approaches. 
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 Potential interaction partners of SNAMA proteins have been isolated, 
although these await further confirmation through experimental validation. 
A strong candidate is DREF, which was isolated in this study as well as by 
our group in an independent study. DREF has a role consistent with 
known functions of Snama. 
 
4.5 FUTURE WORK 
 
In order to verify the existence of both SNAMA proteins, the co-
immunoprecipitation assays of this study should be repeated. Instead of 
electrophoresing the eluted immune complexes via SDS-PAGE, the elutions 
should be sequenced via LC-MS/MS, directly. Given the capabilities of software 
used for identifying protein fragments, a search can be optimised for a protein of 
interest (Stoychev, S., personal communication) – in this case, the search should 
be optimised for SNAMA proteins. This approach would confirm the existence of 
any SNAMA proteins and would also clarify whether the absence of SNAMA-PA 
is attributable to its surmised inability to migrate on standard Laemmli gels. 
 
Finally, given that DREF was isolated in both this study and in an independent 
study by our group, as well as the credible reasons given in Section 4.3, for it 
being a potential interaction partner for SNAMA proteins, the possibility of these 
two proteins being interaction partners should be investigated.  
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CHAPTER FIVE 
 
5. APPENDICES 
 
       APPENDIX A 
 
 
Figure A1: Fermentas PageRulerTM Prestained Protein Ladder. 
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   APPENDIX B 
  
 
Figure B1: Novagen pET-41a(+) expression vector. The vector is transcribed from the 
transcriptional start site located at position 1166 b.p. until the terminator region located at 
positions 72-26 b.p. 
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Figure B2: Tags and cloning features of the pET-41a(+) vector over the region 1095-142 
basepairs. While this sequence forms only part of the open reading frame of the pET-41a(+) vector 
(refer to Figure B1), following induction of protein expression, only the resultant transcript of the 
above sequence is translated. The ATG at the beginning of the GST-tag corresponds to the AUG 
from which translation is initiated, which terminates immediately after the GAT at the end of this 
sequence. 
 
 
ATGTCCCCTATACTAGGTTATTGGAAAATTAAGGGCCTTGTGCAACCCACTCGACT
TCTTTTGGAATATCTTGAAGAAAAATATGAAGAGCATTTGTATGAGCGCGATGAAG
GTGATAAATGGCGAAACAAAAAGTTTGAATTGGGTTTGGAGTTTCCCAATCTTCCT
TATTATATTGATGGTGATGTTAAATTAACACAGTCTATGGCCATCATACGTTATAT
AGCTGACAAGCACAACATGTTGGGTGGTTGTCCAAAAGAGCGTGCAGAGATTTCAA
TGCTTGAAGGAGCGGTTTTGGATATTAGATACGGTGTTTCGAGAATTGCATATAGT
AAAGACTTTGAAACTCTCAAAGTTGATTTTCTTAGCAAGCTACCTGAAATGCTGAA
AATGTTCGAAGATCGTTTATGTCATAAAACATATTTAAATGGTGATCATGTAACCC
ATCCTGACTTCATGTTGTATGACGCTCTTGATGTTGTTTTATACATGGACCCAATG
TGCCTGGATGCGTTCCCAAAATTAGTTTGTTTTAAAAAACGTATTGAAGCTATCCC
ACAAATTGATAAGTACTTGAAATCCAGCAAGTATATAGCATGGCCTTTGCAGGGCT
GGCAAGCCACGTTTGGTGGTGGCGACCATCCTCCAAAATCGGATGGTTCAACTAGT
GGTTCTGGTCATCACCATCACCATCACTCCGCGGGTCTGGTGCCACGCGGTAGTAC
TGCAATTGGTATGAAAGAAACCGCTGCTGCTAAATTCGAACGCCAGCACATGGACA
GCCCAGATCTGGGTACCGGTGGTGGCTCCGGTGATGACGACGACAAGAGTCCCATG
GGATATCGGGGATCCGAATTCTGTACAGGCCTTGGCGCGCCTGCAGGCGAGCTCCG
TCGACAAGCTTGCGGCCGCACTCGAGCACCACCACCACCACCACCACCACTAATTG
AT 
KEY: 
ATG...GAT (position 1095 – 436 of vector)   = GST tag  
CATCACCATCACCATCAC (414 - 397)  = Hexa-HIS tag 
CTGGTGCCACGCGGTAGT (387 - 370)  = Thrombin cleavage site 
AAA...AGC (354 - 310)    = S-tag 
GATGACGACGACAAG ( 274 - 260)   = Enterokinase cleavage site 
Underlined sequences (GAC...GAG) (265 - 174)  = Multiple cloning site 
G’GATCC             = BamHI 
A’AGCTT            = HindIII 
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       APPENDIX C 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C1: Amino acid sequence of the 36 kDa control protein. The colour-coded nucleotide 
sequence (refer to the key in Figure B2) is shown in the line above the amino acid sequence.  
 
         
Translation of Control protein   
Universal code 
Total amino acid number: 318, MW=35675 
 
1         ATGTCCCCTATACTAGGTTATTGGAAAATTAAGGGCCTTGTGCAACCCACTCGACTTCTT 
1          M  S  P  I  L  G  Y  W  K  I  K  G  L  V  Q  P  T  R  L  L   
 
61        TTGGAATATCTTGAAGAAAAATATGAAGAGCATTTGTATGAGCGCGATGAAGGTGATAAA 
21         L  E  Y  L  E  E  K  Y  E  E  H  L  Y  E  R  D  E  G  D  K   
 
121       TGGCGAAACAAAAAGTTTGAATTGGGTTTGGAGTTTCCCAATCTTCCTTATTATATTGAT 
41         W  R  N  K  K  F  E  L  G  L  E  F  P  N  L  P  Y  Y  I  D   
 
181       GGTGATGTTAAATTAACACAGTCTATGGCCATCATACGTTATATAGCTGACAAGCACAAC 
61         G  D  V  K  L  T  Q  S  M  A  I  I  R  Y  I  A  D  K  H  N   
 
241       ATGTTGGGTGGTTGTCCAAAAGAGCGTGCAGAGATTTCAATGCTTGAAGGAGCGGTTTTG 
81         M  L  G  G  C  P  K  E  R  A  E  I  S  M  L  E  G  A  V  L   
 
301       GATATTAGATACGGTGTTTCGAGAATTGCATATAGTAAAGACTTTGAAACTCTCAAAGTT 
101        D  I  R  Y  G  V  S  R  I  A  Y  S  K  D  F  E  T  L  K  V   
 
361       GATTTTCTTAGCAAGCTACCTGAAATGCTGAAAATGTTCGAAGATCGTTTATGTCATAAA 
121        D  F  L  S  K  L  P  E  M  L  K  M  F  E  D  R  L  C  H  K   
 
421       ACATATTTAAATGGTGATCATGTAACCCATCCTGACTTCATGTTGTATGACGCTCTTGAT 
141        T  Y  L  N  G  D  H  V  T  H  P  D  F  M  L  Y  D  A  L  D   
 
481       GTTGTTTTATACATGGACCCAATGTGCCTGGATGCGTTCCCAAAATTAGTTTGTTTTAAA 
161        V  V  L  Y  M  D  P  M  C  L  D  A  F  P  K  L  V  C  F  K   
 
541       AAACGTATTGAAGCTATCCCACAAATTGATAAGTACTTGAAATCCAGCAAGTATATAGCA 
181        K  R  I  E  A  I  P  Q  I  D  K  Y  L  K  S  S  K  Y  I  A   
 
601       TGGCCTTTGCAGGGCTGGCAAGCCACGTTTGGTGGTGGCGACCATCCTCCAAAATCGGAT 
201        W  P  L  Q  G  W  Q  A  T  F  G  G  G  D  H  P  P  K  S  D   
 
661       GGTTCAACTAGTGGTTCTGGTCATCACCATCACCATCACTCCGCGGGTCTGGTGCCACGC 
221        G  S  T  S  G  S  G  H  H  H  H  H  H  S  A  G  L  V  P  R   
 
721       GGTAGTACTGCAATTGGTATGAAAGAAACCGCTGCTGCTAAATTCGAACGCCAGCACATG 
241        G  S  T  A  I  G  M  K  E  T  A  A  A  K  F  E  R  Q  H  M   
 
781       GACAGCCCAGATCTGGGTACCGGTGGTGGCTCCGGTGATGACGACGACAAGAGTCCCATG 
261        D  S  P  D  L  G  T  G  G  G  S  G  D  D  D  D  K  S  P  M   
 
841       GGATATCGGGGATCCGAATTCTGTACAGGCCTTGGCGCGCCTGCAGGCGAGCTCCGTCGA 
281        G  Y  R  G  S  E  F  C  T  G  L  G  A  P  A  G  E  L  R  R   
 
901       CAAGCTTGCGGCCGCACTCGAGCACCACCACCACCACCACCACCACTAATTGAT 
301        Q  A  C  G  R  T  R  A  P  P  P  P  P  P  P  L  I  D   
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Translation of SNAMA DCM protein 
Universal code 
Total amino acid number: 559 AA, MW=63120 
 
1   ATGTCCCCTATACTAGGTTATTGGAAAATTAAGGGCCTTGTGCAACCCACTCGACTTCTT 
1    M  S  P  I  L  G  Y  W  K  I  K  G  L  V  Q  P  T  R  L  L   
 
61  TTGGAATATCTTGAAGAAAAATATGAAGAGCATTTGTATGAGCGCGATGAAGGTGATAAA 
21   L  E  Y  L  E  E  K  Y  E  E  H  L  Y  E  R  D  E  G  D  K   
 
121 TGGCGAAACAAAAAGTTTGAATTGGGTTTGGAGTTTCCCAATCTTCCTTATTATATTGAT 
41   W  R  N  K  K  F  E  L  G  L  E  F  P  N  L  P  Y  Y  I  D   
 
181 GGTGATGTTAAATTAACACAGTCTATGGCCATCATACGTTATATAGCTGACAAGCACAAC 
61   G  D  V  K  L  T  Q  S  M  A  I  I  R  Y  I  A  D  K  H  N   
 
241 ATGTTGGGTGGTTGTCCAAAAGAGCGTGCAGAGATTTCAATGCTTGAAGGAGCGGTTTTG 
81   M  L  G  G  C  P  K  E  R  A  E  I  S  M  L  E  G  A  V  L   
 
301 GATATTAGATACGGTGTTTCGAGAATTGCATATAGTAAAGACTTTGAAACTCTCAAAGTT 
101  D  I  R  Y  G  V  S  R  I  A  Y  S  K  D  F  E  T  L  K  V   
 
361 GATTTTCTTAGCAAGCTACCTGAAATGCTGAAAATGTTCGAAGATCGTTTATGTCATAAA 
121  D  F  L  S  K  L  P  E  M  L  K  M  F  E  D  R  L  C  H  K   
 
421 ACATATTTAAATGGTGATCATGTAACCCATCCTGACTTCATGTTGTATGACGCTCTTGAT 
141  T  Y  L  N  G  D  H  V  T  H  P  D  F  M  L  Y  D  A  L  D   
 
481 GTTGTTTTATACATGGACCCAATGTGCCTGGATGCGTTCCCAAAATTAGTTTGTTTTAAA 
161  V  V  L  Y  M  D  P  M  C  L  D  A  F  P  K  L  V  C  F  K   
 
541 AAACGTATTGAAGCTATCCCACAAATTGATAAGTACTTGAAATCCAGCAAGTATATAGCA 
181  K  R  I  E  A  I  P  Q  I  D  K  Y  L  K  S  S  K  Y  I  A   
 
601 TGGCCTTTGCAGGGCTGGCAAGCCACGTTTGGTGGTGGCGACCATCCTCCAAAATCGGAT 
201  W  P  L  Q  G  W  Q  A  T  F  G  G  G  D  H  P  P  K  S  D   
 
661 GGTTCAACTAGTGGTTCTGGTCATCACCATCACCATCACTCCGCGGGTCTGGTGCCACGC 
221  G  S  T  S  G  S  G  H  H  H  H  H  H  S  A  G  L  V  P  R   
 
721 GGTAGTACTGCAATTGGTATGAAAGAAACCGCTGCTGCTAAATTCGAACGCCAGCACATG 
241  G  S  T  A  I  G  M  K  E  T  A  A  A  K  F  E  R  Q  H  M   
 
781 GACAGCCCAGATCTGGGTACCGGTGGTGGCTCCGGTGATGACGACGACAAGAGTCCCATG 
261  D  S  P  D  L  G  T  G  G  G  S  G  D  D  D  D  K  S  P  M   
 
841 GGATATCGGGGATCCATGTCGGTACACTATAAATTTAAGAGTACACTCAACTTTGATACA 
281  G  Y  R  G  S  M  S  V  H  Y  K  F  K  S  T  L  N  F  D  T   
 
901 ATTACTTTTGATGGACTTCACATTTCTGTCGGGGACTTAAAAAGGGAGATTGTGCAGCAG 
301  I  T  F  D  G  L  H  I  S  V  G  D  L  K  R  E  I  V  Q  Q   
 
961 AAGCGACTGGGCAAAATCATCGACTTTGATCTCCAAATAACAAATGCGCAGAGTAAAGAA 
321  K  R  L  G  K  I  I  D  F  D  L  Q  I  T  N  A  Q  S  K  E   
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Figure D1: Amino acid sequence of the 63 kDa SNAMA DCM protein. The first 285 amino acids 
at the amino-terminus are identical to that of the control protein (refer to Figure C1 as well as the 
key in Figure B2 for colour-coded regions). Amino acids 286 to 545, high-lighted in dark blue 
with corresponding nucleotide sequence in blue lettering, code for the SNAMA DCM. A 
frameshift is introduced at the HindIII restriction site (high-lighted in yellow) where the SNAMA 
DCM carboxy-terminus is fused to the vector. As a result, the sequence downstream of HindIII 
differs between the control and SNAMA DCM proteins; the frameshift results in an additional 
octa-HIS-tag at the carboxy-terminus of the SNAMA DCM protein, followed by a stop-codon.  
 
 
 
 
 
 
1021 GAATACAAGGACGATGGGTTCCTTATTCCCAAAAACACAACGCTGATCATATCGCGCATC 
341   E  Y  K  D  D  G  F  L  I  P  K  N  T  T  L  I  I  S  R  I   
 
1081 CCCATCGCCCATCCCACAAAAAAGGGCTGGGAGCCACCAGCAGCAGAAAATGCCTTTTCG 
361   P  I  A  H  P  T  K  K  G  W  E  P  P  A  A  E  N  A  F  S   
 
1141 GCGGCGCCTGCCAAGCAGGACAACTTCAACATGGACCTGTCCAAAATGCAAGGCACGGAG 
381   A  A  P  A  K  Q  D  N  F  N  M  D  L  S  K  M  Q  G  T  E   
 
1201 GAGGACAAAATCCAGGCCATGATGATGCAGAGCACAGTCGACTATGATCCTAAGACGTAC 
401   E  D  K  I  Q  A  M  M  M  Q  S  T  V  D  Y  D  P  K  T  Y   
 
1261 CATCGTATTAAAGGACAATCGCAAGTGGGAGAAGTTCCCGCATCCTACCGATGCAACAAA 
421   H  R  I  K  G  Q  S  Q  V  G  E  V  P  A  S  Y  R  C  N  K   
 
1321 TGCAAGAAAAGCGGACACTGGATCAAAAACTGTCCCTTTGTGGGGGGAAAGGACCAGCAA 
441   C  K  K  S  G  H  W  I  K  N  C  P  F  V  G  G  K  D  Q  Q   
 
1381 GAGGTCAAACGGAATACTGGTATTCCGCGGTCTTTCCGCGACAAGCCAGATGCGGCTGAG 
461   E  V  K  R  N  T  G  I  P  R  S  F  R  D  K  P  D  A  A  E   
 
1441 AACGAATCAGCCGATTTTGTGCTGCCTGCTGTACAAAACCAAGAGATACCGGAGGATCTG 
481   N  E  S  A  D  F  V  L  P  A  V  Q  N  Q  E  I  P  E  D  L   
 
1501 ATATGCGGCATATGCCGAGATATATTCGTCGATGCTGTCATGATACCCTGCTGCGGAAGT 
501   I  C  G  I  C  R  D  I  F  V  D  A  V  M  I  P  C  C  G  S   
 
1561 TCCTTTTGTGACGACTGTGTGCGAACCTCCTTATTGGAGTCAGAGGATAGTGAGTGCCCC 
521   S  F  C  D  D  C  V  R  T  S  L  L  E  S  E  D  S  E  C  P   
 
1621 GATTGCAAGGAGAAGCTTGCGGCCGCACTCGAGCACCACCACCACCACCACCACCACTAA 
541   D  C  K  E  K  L  A  A  A  L  E  H  H  H  H  H  H  H  H  *   
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           APPENDIX E 
 
Figure E1: MALDI-TOF identification of positive control protein. SNAMA is a Xhosa word 
meaning “something that sticks like glue” (Mather, 2005; Mather et al., 2005). The 1231 a.a. 
sequence shown here is thus SNAMA-PA – refer to Figure 1.4. Residues in red lettering represent 
fragments of the positive control protein identified by MALDI-TOF. With the exception of the six 
residue long fragment spanning residues 588-593, all fragments correspond to the DCM region of 
SNAMA.  
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